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CHAPTER 1  
This thesis focuses on the health economic evaluation and implementation 
of pharmacogenetics (PGx) in clinical practice. PGx is a form of personalized 
medicine, which is rapidly growing in the last few years. However, for successful 
clinical implementation in clinical practice, evaluation of the cost-effectiveness 
and potential barriers and facilitators is an important step. 
Personalized medicine
There is no universally accepted definition of personalized medicine. In Europe 
the following definition of the Horizon 2020 Advisory Group is often used:
 "a medical model using characterization of individuals’ phenotypes and genotypes 
(e.g. molecular profiling, medical imaging, lifestyle data) for tailoring the right 
therapeutic strategy for the right person at the right time, and/or to determine 
the predisposition to disease and/or to deliver timely and targeted prevention" (1).
Personalized medicine takes individual patient characteristics into account in 
order to improve risk assessment, diagnosis, prognosis and treatment. As seen 
from the definition, there are many forms of personalized medicine in therapy, 
prevention and screening. In this thesis, we focus on targeting medication based 
on genotype, so called PGx.This form of personalized medicine is an answer to 
the generally used ‘one size fits all’ approach by which the same treatment and 
the some dosage is used for each and every patient. However, the responses to 
these standard treatments could vary between individuals, as some patients could 
experience adverse drug reactions (ADRs) and others could have insufficient effect 
of the treatment. This may be one of the explanations that about 5% of all acute 
hospitalizations are caused by an ADR worldwide (2). In the Netherlands, this 
corresponds to about 19.000 hospitalizations per year and societal costs of more 
than 85 million Euros (3).
Pharmacogenetics
In the field of PGx, associations are investigated between individual drug responses, 
in the form of ADRs or ineffective treatments, for patients with specific genotypes. 
The assumption is that adjusting and thereby optimizing treatment on this genetic 
information could prevent ADR or improve effectiveness for the individual patient. 
This has also led to several initiatives developing guidelines concerning drug/dose 
recommendations for different gene-drug interactions. At the moment, there 
are more than 100 dosing guidelines, most of these developed by the Clinical 
Pharmacogenetics Implementation Consortium (CPIC), the Royal Dutch Association 
for the Advancement of Pharmacy - Pharmacogenetics Working Group  (DPWG), 
and the Canadian Pharmacogenomics Network for Drug Safety (CPNDS) (4-6). In 




EMA (European Medicines Agency) approved drugs, PGx information is included 
(7, 8). However, the PGx information and related recommendations could differ 
between the two institutes, for example ‘testing required’, ‘testing recommended’, 
‘actionable PGx’ or ‘informative PGx’. The first two recommendations are explicitly 
stating PGx testing when prescribing a specific agent, while the other states that 
genes are involved in the metabolism of a drug which not necessarily lead to a 
different response. 
We are still in the early days of implementation of PGx testing in clinical practice, 
as advises of specific treatments or dosages for patients with specific genetic 
variants are still lacking and/or important scientific evidence is missing. For 
example, in case of CYP2D6, which is part of the cytochrome P450 enzyme system 
and involved in the metabolism of drugs, people with variations in the gene 
coding for CYP2D6 have no or little, normal, or increased activity of the CYP2D6 
enzyme. According to this genetic information, patients are classified as ‘poor’, 
‘normal’ or ‘ultra’ metabolizers. Patients with lower enzyme activity (‘poor’) are at 
risk of developing ADRs, and patients with higher enzyme activity (‘ultra’) could 
have less treatment effectiveness when receiving standard treatment. For these 
patients a lower dosage (‘poor’) or increased dosage (‘ultra’) is recommended. 
Currently, there seems however a lack of evidence concerning the clinical 
relevance and cost-effectiveness of this genotype guided treatment (9, 10). Do 
these recommendations of optimizing drug treatment really lead to less ADRs or 
increased effectiveness? And does testing every person for their genotype offers 
us ‘value for money’ by improving drug treatment at acceptable costs? In most 
cases there is a trade-off between the number of patients that need to be tested 
and the effectiveness gain in those who receive dose optimisation based on their 
genetic variant, as costs reductions and effect gains could take place by preventing 
side effects and optimize treatment. Evidence surrounding clinical usefulness 
and cost-effectiveness is a crucial step when we look at effective implementation 
of changes in clinical practice (11). Health Technology Assessment (HTA) is the 
field that studies some of these short- and long term consequences of health 
technologies and new innovations like PGx (12).
Health Technology Assessment 
HTA is a tool to support decision making in health care, by using a multidisciplinary 
process that evaluates the medical, social, economic and ethical issues related 
to the use of a health intervention or technology (12, 13). Its aim is to promote 
safe, effective, and cost-effective health policies and seek to achieve best ‘value’, 
depending on the perspective taken. One of the tools most often used within an 
HTA is an economic evaluation. In an economic evaluation the costs of different 
interventions are related to their benefits, which can either be expressed as 
clinical effect such as adverse drug reactions or hospital admissions, or as quality-
12
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adjusted life years (QALYs). QALYs is a combination of the health-related quality 
of life (HRQoL) and the time spend in that health state. The HRQoL is expressed 
as an utility, which represents the preference for a certain health state, where one 
represents perfect health and zero represents death (14).
The main question in an economic evaluation is: do we get value (in this case 
effect) for money with a new innovation compared to usual care? This is described 
by a so called incremental cost-effectiveness ratio (ICER), which expresses the 
amount of money you have to pay extra to gain one unit of effect, for instance 
a QALY, with your intervention compared to the alternative strategy. Depending 
on the willingness to pay (WTP) of society to gain one unit of effect, we say that 
with the new intervention we get value for money or not, or in other words it 
is cost-effective or not. This WTP could however differ between countries (15). A 
cost-effectiveness (CE) analysis can be trial-based or performed with a modelling 
approach. In the first case, health care resources used and effectiveness (i.e. 
amount of ADRs or QALYs) are measured and analysed alongside a clinical trial. 
In the second case of a modelling approach, the probabilities of different options 
and outcomes and their related costs and benefits are modelled over time and a 
prediction is made about the impact of an intervention on the costs and effects. 
Such a model is well suited to evaluate the impact of different parameters on 
the ICER, and to determine a threshold at which an intervention could become 
cost-effective compared to usual care (16). Both these types of CE-analysis can 
be used to evaluate if PGx is equally or more effective and how it influences the 
costs of healthcare, compared to standard care. The results could be used for 
guiding further research and/or policy decisions. At the moment, many economic 
evaluations are based on a modelling approach in order to timely see possible 
implications of a new intervention. Trial based approaches have a higher internal 
validity but are very time consuming and delivers evidence at a much lower pace 
(17, 18). 
Pharmacogenetics and HTA
There is limited evidence concerning the cost-effectiveness of PGx, and even less 
when focussing on evaluations of existing dosing recommendations. Recent meta-
analyses about this topic found between the 40-80 studies, depending on the 
inclusion criteria (19-22). Most of these economic evaluations investigated testing 
and acting on the same genes; for instance HLA-B (+ HLA-A), TPMT, CYP2C9, CYP2C19 
(+ VKORC1), factor V Leiden, UGT1A1, or KRAS (+ BRAF). More than half of these studies 
found cost savings or cost-effective results of PGx testing. Only a limited amount 
of these studies were based on evidence found in randomised controlled trials or 
other prospective data (23-29). As long as this evidence is not available, modelling 
studies will be required to get an idea of the implications of PGx (17). However, 




the outcomes difficult to compare, as it is not clear what we are willing to pay for 
an effect, other than a QALY, of different interventions, for instance a prevented 
ADR (14). Also, there are still a lot of gene-drug interactions not investigated (9, 
21). In order to successfully implement PGx in practice, increasing the critical mass 
concerning this evidence is necessary. 
Aim of this thesis
The aims of this theses are related to the implementation of PGx in clinical practice, 
and are therefore twofold;
1. To evaluate the cost-effectiveness of implementing various gene-drug 
interactions and related PGx-based optimization strategies in clinical 
practice, compared to current practice. 
2. To evaluate conditions, including barriers and promoters, for (successful) 
implementation of PGx in clinical practice.
Thesis outline
This thesis is divided in two parts. The first part concerns the economic evaluation 
of different gene-drug interactions and related PGx-based optimization strategies. 
We performed two modelling studies and one trial based approach, and choose 
to evaluate a broad spectrum of PGx strategies. The first study concerns the 
interaction between the CYP2D6 gene and the usage of antidepressants in 
patients with major depressive disorder (chapter 2). This study mainly focussed 
on preventing ADRs by using PGx, and to lesser extent increasing effectiveness 
of antidepressants. The second study concerns the interaction between the 
OPRM1 gene and the use of naltrexone or acamprosate in patients with alcohol 
use disorders (chapter 3). This case study was chosen to see the influence of PGx 
on guiding treatment allocation of patients in order to increase effectiveness of 
certain drugs. The trial based study focusses on genotype TPMT-guided thiopurine 
treatment in patients with inflammatory bowel diseases (chapter 4). This study 
shows the influence of PGx testing in a real life setting. 
The second part of this thesis focuses on important conditions for successful 
implementation of PGx in clinical practice. The first chapter describes how we 
preferably should evaluate this kind of new innovations in the light of making 
healthcare more affordable (chapter 5). The second chapter concerns a study 
to evaluate the barriers and facilitators that relevant stakeholders perceive to 
successfully use PGx in their daily routine at the moment (chapter 6). In the last 
chapter we conclude this thesis with a general discussion about the implications 
of our findings, and give some directions for further research (chapter 7). 
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2CHAPTER 2An economic model of the cost-utility of pre-emptive genetic testing to support pharmacotherapy in patients with major depression in primary care
 Sluiter RL, Janzing JGE, van der Wilt GJ, Kievit W, 
Teichert M.




The pharmacokinetics of many antidepressants (tricyclic antidepressants (TCA) 
or selective serotonin re-uptake inhibitors (SSRI)) are influenced by the highly 
polymorphic CYP2D6 enzyme. Therefore, pharmacogenetics could play an 
important role in the treatment of depressive patients. The potential cost-utility 
of screening patients is however still unknown. Therefore, a Markov model was 
developed to compare the strategy of screening for CYP2D6 and subsequently 
adjust antidepressant treatment according to a patient’s metabolizer profile of 
poor, extensive, or ultra metabolizer, with the strategy of no screening (‘one size 
fits all’ principle). Each week a patient had a probability of side effects which was 
followed by dosage titration or treatment switching. After 6 weeks treatment 
effect was evaluated followed by treatment adjustments if necessary, with a total 
time horizon of the model of 12 weeks. The analysis was performed from a societal 
perspective. The strategy of screening compared with no screening resulted in 
incremental costs of €91 (95 percentiles: €45 - €151) more expensive but also more 
effect with 0.001 quality adjusted life years (QALYs) (95 percentiles: 0.0004 - 0.002) 
gain. The incremental cost-effectiveness ratio (ICER) was therefore € 77,406 per 
QALY gained, but varied between €22,500 and €377,500 depending on the price of 
screening and productivity losses. According to our model, we cannot unequivocally 
conclude that screening for CYP2D6 in primary care patients using antidepressants 
is cost-effective, as the results are surrounded by large uncertainty. Therefore, 
information from ongoing studies should be used to reduce these uncertainties.
Keywords: CYP2D6, pharmacogenetics, antidepressants, cost-effectiveness 
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Introduction 
Major depressive disorder has a prevalence of about 7% in the European population 
and is associated with a high burden for both, patients and society at large (1). 
In Europe, the annual total costs of treatment of patients with mood disorders, 
including depressive disorders, are about €113 billion, including direct healthcare 
costs, direct non-medical costs and indirect costs (2). Despite the availability of 
different drug classes to treat depressive disorders, about 30-50% of patients 
gain insufficient benefit from initial treatment (3). At present, antidepressant drug 
therapy is monitored by the incidence of side effects and treatment response. 
In the absence of reliable predictors for efficacy, drug treatment for depression 
is to a large extent a matter of trial and error.(4) Whereas side effects with 
antidepressants can occur immediately, clinical response is usually evaluated after 
4-6 weeks after instalment of treatment (5). Consequently, treatment adjustment 
currently is usually not timely (6-8). Reliable prediction of treatment response on 
antidepressants could shorten present trial and error cycles and, thereby, improve 
antidepressant treatment for patients and reduce costs. 
Pharmacogenetics could be a predictor of individual treatment response and side 
effects, by relating differences in responses to variation in the genes involved in 
the metabolisation of drugs. An important role in these differences is played by 
the cytochrome P450 enzyme system, in which a number of polymorphisms were 
detected in the gene coding for the CYP2D6 enzyme (9, 10). The CYP2D6 enzyme 
is involved in the metabolisation of approximately 25% of all drugs, including 
tricyclic antidepressants (TCA) (e.g. amitrptyline and nortriptyline) and selective 
serotonin re-uptake inhibitors (SSRIs) (e.g. paroxetine, fluoxetine and fluvoxamine) 
(9-11). Differences in the CYP2D6 genotype were shown to contribute to the drug 
response with antidepressants (3, 4, 6, 7, 12-16).
Depending on the presence of functional alleles, different metaboliser groups 
of the CYP2D6 function were defined. Poor metabolisers (PMs) (7-10% of the 
Caucasian population) are patients with no active allele of CYP2D6, and, therefore, a 
decreased metabolic activity; extensive metabolisers (EMs) have one or two active 
alleles of CYP2D6 (85-90% of the Caucasian population) and a normal metaboliser 
activity; ultra metabolisers (UMs) have more than two active alleles of CYP2D6 and 
increased enzymatic activity (2% of the Caucasian population) (3, 12, 17, 18). Due to 
a lower CYP2D6 enzyme activity, patients with PM phenotypes were shown to have 
higher serum concentrations of CYP2D6 substrates compared to EMs, and are, 
therefore, are at higher risk of side effects from treatment with antidepressants 
(19, 20). Correspondingly, UM patients with lower serum concentrations of CYP2D6 
substrates than EM, probably show lower treatment effectiveness (21). 
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These pharmacogenetic parameters were translated into therapeutic 
recommendations that recommend dosage adaption according to genotypes by 
initiatives like the Clinical Pharmacogenetics Implementation Consortium and the 
Royal Dutch Pharmacists Association - Pharmacogenetics Working Group (22, 23). 
Pre-emptive pharmacogenetic testing on CYP2D6 genotypes could, thus, influence 
the choice for a drug (whether or not metabolised by CYP2D6) or the dosage (with 
a lower dosage for PM and a higher dosage for UM) and improve timely treatment 
optimisation. The feasibility of pharmacogenetic screening for CYP2D6 genotypes 
in primary care has been demonstrated (24).
Despite the feasibility of genetic testing and the availability of dosage 
recommendations for CYP2D6 genotypes, there is a lack of evidence on the clinical 
effectiveness and the cost-utility of such approach. Results concerning treatment 
outcomes are not stratified by CYP2D6 metabolizer class or looked at outcome 
measures, as for instance ‘switching’ or efficacy, not directly reflecting side effects 
or remission. Also, the few described studies are most of the time focussed on 
venlafaxine (25). Evidence about the clinical effectiveness is necessary in order to 
support decisions on implementation of pharmacogenetic tests in clinical practice 
(26-29). Besides collecting clinical evidence, an economic model can provide an 
indication of the cost-utility of pharmacogenetic screening of CYP2D6 variant alleles 
and individualised dosage adjustment. In sensitivity analyses, the influences of 
uncertainties due to gaps in knowledge and evidence can be explored (30-32). 
Future clinical studies could focus on collecting data concerning those parameters 
that have the largest influence on cost-effectiveness.
The aim of this study was to assess the likely cost-utility of pharmacogenetic 
screening (‘PGx’) for CYP2D6 genotypes before the start of antidepressant drug 
treatment, compared to current practice (‘no PGx’).
23




A Markov model was constructed to represent clinical practice. This model was 
based on actual clinical guidelines (5, 33) and clinical expertise of psychiatrists. 
The model ran with a cycle length of 1 week, with a maximum number of 12 
cycles. This choice was made as no additional value of ‘PGx’ was expected after 
two treatment cycles of 6 weeks, and the same treatment adjustments could then 
be made on the basis of a patient’s phenotype. Part of the model is presented in 
Fig. 1, in which the ‘PGx’ strategy was compared to the ‘no PGx’ strategy in adult 
patients with major depression (age ≥ 18 years) in primary care. A hypothetical 
cohort of 1000 patients was used in the model. The analysis was performed from 
a societal perspective, which means that all costs relevant for society were taken 
into account including productivity losses. 
In antidepressant treatment, patients experience side effects usually earlier than 
treatment effects. If a side effect occurs within the first week, the model offers three 
options: dosage adjustment (titration): a switch to a different drug or no adjustments 
with a ‘wait-and-see’ approach. When titration or a switch occurred, patients again 
had a chance of experiencing side effects during the following week. The patients 
without side effects continue their treatment during this period. After 6 weeks, 
patients (without side effects or no adjustments) had a probability for a clinical 
response. Subsequently, for the phenotype ‘no clinical improvement’ (also called ‘no 
effect’), patients were at risk of a suicide attempt. In case of a failed attempt, a switch 
to a different drug was assumed, with outcomes similar to those of patients who did 
not show clinical improvement and who did not attempt suicide.
In the strategy of ‘no PGx’, patients with the different metaboliser profiles receive 
standard care . Based on side effects and/or drug effectiveness (phenotype), 
potential treatment adjustments are made for these patients in order to find the 
optimal treatment. In the strategy of ‘PGx’, patients are tested on CYP2D6 variants 
and receive a drug dosage based on the corresponding genotype at the start of 
the treatment. This adjustments should lead to better treatment outcomes (less 
side effects and more effects).
24
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Figure 1. Model for evaluating cost-utility of pharmacogenetic screening. Each week a patient had a probability 
of side effects, which was followed by treatment adjustments, including dosage titration or switching, or no 
treatment adjustments and wait (due to no serious effects). Patients with no side effects continued treatment. 
After six weeks, the treatment effect for each patient was evaluated, and switched, as appropriate. Patients with 
clinical improvement continued treatment. Patients who did not demonstrate clinical improvement with 
treatment were switched to other antidepressants. A proportion of these patients attempted suicide, successfully 
or not. The part of the model that is not presented contains the differentiation of patients as PM, EM or UM.
Model input
For the different model parameters scientific evidence was searched, and if 
necessary assumptions were made and discussed with clinical experts. As 
mentioned in the introduction, there is not much evidence that stratifies treatment 
outcomes by CYP2D6 metabolizer class. This study therefore focussed on the 
antidepressant that had the strongest associated effect with CYP2D6, venlafaxine, 
and made assumptions for the other antidepressants. 
Probabilities
First, in both strategies patients were divided into the three metaboliser classes: 
PM, EM, or UM. This was based upon prevalence data amongst (Caucasian) 
depressive patients (17, 18). In scientific literature also intermediate metabolisers 
are described, which are patients with no or less active allele of CYP2D6, and 
therefore a decreased metabolic activity. In our model we included this group in 
PM group, as they receive the same treatment adjustments. 
For the ‘no PGx’ strategy, the risks of experiencing side effects (without pre-
emptive dosage adjustments) due to a patient's metaboliser class were based 
upon the study by Shams et al. (20). Concerning treatment effects, a general effect 
among depressive patients was assumed for the EM class. This effect was based 
25
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upon a study on remission rates among depressive patients (34). Due to the lack 
of evidence for PM and UM metabolisers, assumptions on treatment effects had 
to be made. For the PM group with an increased antidepressant blood level, the 
same treatment effect as for the EM group was assumed. For the UM group with 
a decreased antidepressant blood level, a smaller treatment effect was assumed. 
The probabilities of dosage titration, switching or waiting due to side effects or no 
treatment effect, and suicide attempts were derived from the cost-effectiveness 
study by Annemans et al. (35). These probabilities were assumed to be equal for 
those without treatment effects, regardless of the metaboliser classes. In the 
second loop, it was assumed that dosages were adjusted based on a patient’s 
phenotype (side effect or effect occurrence). This means that then the chances of 
EM were used in this loop for every patient. 
For the ‘PGx’ strategy, it was assumed that for every patient the dosages and 
treatment were optimised at the start of treatment. This means that treatment 
was adjusted for a patient’s genetic profile and corresponding CYP2D6 activity. 
Due to lack of data, we assumed that the probabilities for side effect and clinical 
improvement corresponded to the probabilities of the EM class. In other words, 
patients with PM or UM profile had the same probability of sustaining side effects 
or treatment effects as the EM group. 
Costs
The costs for each strategy were determined by medication costs per week, costs 
for visits to the general practitioner (GP) - or psychiatrist, and productivity losses. 
These costs were based on standard prices valued by the National Healthcare 
Institute (36, 37). GP visits were planned each time when side effects occurred 
and potential treatment adjustments needed to be made. When no treatment 
effect was achieved, the patient was referred to a psychiatrist in order to switch 
treatment. Costs associated with (fatal) suicide attempts were based on studies 
by Annemans et al. and Demyttenare et al., and included direct costs due to the 
attempt itself, plus follow-up cost including hospitalisation (35, 38). Productivity 
losses were assumed for patients experiencing side effects or no treatment 
effect, and were calculated by multiplying the time absent from work due to their 
depressive disorder with a standard hourly labour cost (37). The time absent from 
work was based upon data from NEMESIS study, which investigated the psychic 
conditions and related consequences of the adult population in the Netherlands 
(37, 39, 40). For ‘PGx’, genetic screening costs were also included, which were 
based upon clinical information from the Department of Human Genetics of the 





Quality adjusted life years (QALYs) were the outcome measure for the effectiveness 
of the intervention. A QALY is calculated by multiplying the health-related quality 
of life (HRQoL) and the time spend in this health state. The HRQoL is expressed 
as an utility, representing the preference for a certain health state. A value 
of one represents perfect health, and zero represents death. Utilities for the 
different health states were derived from a study by Koeser et al., which was a 
cost-effectiveness analysis of different treatment options for moderate to severe 
depression (42). For the states related to side effects and related changes in 
treatment (titration or switch), the assumption was made that these patients had 
the same utility as depressive patients at baseline. The utility value for a suicide 
attempt was assumed to be equal to zero. Patients who achieved an effect of 
treatment had an increase in utility.
All parameters are presented in Table 1.
Table 1. Parameters used in the Markov model
Parameter (1 week cycles) Probability 95% CI Reference
Probability to be PM 0.18 0.15 0.19 (17, 18)
Probability to be EM 0.80 0.78 0.82 (17, 18)
Probability to be UM 0.02 0.01 0.03 (17, 18)
Probability side effects being PM 0.90 0.80 0.95 (20)
Probability of no side effects being PM 0.10 0.05 0.20 (20)
Probability side effects being EM 0.49 0.25 0.75 (20)
Probability of no side effects being EM 0.51 0.25 0.75 (20)
Probability side effects being UM 0.30 0.00 0.80 (20)
Probability of no side effects being UM 0.70 0.20 1.00 (20)
Probability side effects being PM after PGx 0.49 0.25 0.75 Assumption
Probability of no side effects being PM after PGx 0.51 0.25 0.75 Assumption
Probability having an effect (remission) being 
PM
0.37 0.30 0.45 (34)
Probability having no effect being PM 0.63 0.55 0.70 (34)
Probability having an effect being EM 0.37 0.30 0.45 (34)
Probability having no effect being EM 0.63 0.55 0.70 (34)
Probability having an effect being UM 0.35 0.15 0.50 Assumption
Probability having no effect being UM 0.65 0.50 0.85 Assumption
Probability having effect being PM after PGx 0.37 0.30 0.45 Assumption
Probability having no effect being PM after PGx 0.63 0.55 0.70 Assumption
27
Cost-utility of pre-emptive CYP2D6 testing in major depressive patients
2
Parameter (1 week cycles) Probability 95% CI Reference
Probability of titration 0.24 0.20 0.30 (35)
Probability of switching (same or another class) 0.52 0.40 0.60 (35)
Probability of waiting 0.25 0.20 0.30 (35)
Probability suicide attempt 0.06 0.03 0.10 (35)
Probability fatal suicide attempt 0.0063 (35)
Utility of being depressed 0.48 0.38 0.58 (42)
Utility of no side effects 0.62 0.54 0.70 (42)
Utility after titration 0.48 0.40 0.50 (42)
Utility after switching 0.48 0.40 0.50 (42)
Utility for waiting 0.62 0.54 0.70 (42)
Utility for effect (remission) 0.80 0.76 0.84 (42)
Utility for no effect 0.48 0.38 0.58 (42)
Utility suicide attempt 0.00 0.00 0.05 (42)
Costs associated with suicide attempt (€) 3,567.88 1,783.94 5,351.83 (35, 38)
Costs fatal suicide(€) 131.24 65.62 196.86 (35, 38)




Costs for GP visit(€) 33.21 (37)
Costs for psychiatrist visit(€) 94.61 (37)
Cost due to labour loss (€/hour) 30.02 (37)
Standard prescription costs pharmacist(€) 6.00 (37)
First prescription costs pharmacist(€) 12.00 (37)
Cost medication for one week(€) fluoxetine 
(SSRI)
0.21 (36)
citalopram (SSRI) 0.21 (36)
venlafaxine (SNRI) 0.53 (36)
mirtazapine (NaSSA) 0.42 (36)
amitryptiline (TCA) 0.70 (36)
nortriptyline (TCA) 3.29 (36)
fluoxetine (SSRI) 0.21 (36)
Amount of hours labour loss (per week) 3.94 1 40 (39, 40)
CI confidence interval, PM poor metaboliser, EM extensive metaboliser, UM ultra metaboliser, GP general 
practitioner, SSRI selective serotonin re-uptake inhibitors, SNRI serotonin–norepinephrine reuptake inhibitors, 




A base case analysis was performed with the deterministic values presented in 
Table 1. The results of these analyses are summarised in incremental costs and 
effects between the two strategies, and an incremental cost-effectiveness ratio 
(ICER). The ICER represents the amount of money that need to be paid to gain 
one QALY with the intervention, compared to usual care. With a Monte Carlo 
simulation of 5,000 iterations, the uncertainty surrounding the point estimates was 
assessed. This was done for each iteration of the parameters that were uncertain 
(Table 1) by choosing a random value from their distribution. These distributions 
were based on the 95% confidence intervals of the specific parameters (except 
productivity losses). Beta distributions were used for probability rates and utilities, 
and gamma distributions for costs (30, 31). For each iteration, incremental costs 
and effects were calculated. The results of these iterations were presented in a 
cost-effectiveness plane (CE-plane). Based on the CE-plane, a cost-effectiveness 
acceptability (CEA) curve was constructed. This CEA curve shows the probability 
that ‘PGx’ is cost-effective compared to ‘no PGx’ for different willingness to pay 
(WTP) thresholds (30).
 A univariate sensitivity analysis was performed to check the uncertainty for each 
parameter separately. This means that each time one parameter was varied by a 
lower- and a higher value than the base case within a certain range. This resulted 
in a Tornado diagram, which showed the range of the ICER due to parameter 
uncertainty.
Also, two scenario analyses were performed. The first scenario took into account 
a delayed effect of a week for the genetic screening, as test results are not always 
immediately at hand to adjust treatment. In our base case analysis we assumed 
no delayed effect, as in the future more and more patients probably have already 
a genetic test result and results will become available much earlier. However, 
this might not the case yet, so therefore we included this scenario. The second 
scenario was without productivity losses taken into account, as these are difficult 
to measure and could lead to a biased estimate. 
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Results
The results of the base case analysis are presented in Table 2. The ‘PGx’ strategy 
resulted in costs of €971 (95 percentiles: 796 - 1,231) and effects of 0.146 (95 
percentiles: 0.133 - 0.159) QALYs per patient, and for the strategy of ‘no PGX’ in 
costs of €879 (95 percentiles: 718 - 1,120) and effects of 0.145 (95 percentiles: 
0.133 - 0.157) QALYs per patient. A comparison between ‘PGx’ and ‘no PGX’ resulted 
in incremental costs of €91 (95 percentiles: 45 - 151) and incremental effects of 
0.001 (95 percentiles: 0.0004 - 0.002) QALY. This resulted in an ICER of €77,406 (95 
percentiles: 22,500 - 377,500) per QALY gained. 
Table 2 Costs and effects of the strategies of ´PGx´ and ´no PGx´
Strategy Costs Incremental costs QALY Incremental QALY
‘PGx’ €971 (€796; €1,231) €91 (€45; €151) 0.146 (0.133; 0.159) 0·001 (0·0004; 0·002)
‘No PGx’ €879 (€718; €1,120) 0.145 (0.133; 0.157)
Costs and QALYs are presented as means with 95 percentiles resulting from Monte Carlo simulation with 
5,000 iterations. 




The Monte Carlo simulation showed that the ICER of the base case was quite 
uncertain, as seen in Fig. 2. In total 48% of the simulations were below the WTP 
threshold of €80,000 per QALY, with corresponding probability that ‘PGx‘ would be 
cost-eff ective given this threshold.
Figure 2. Cost-eff ectiveness (CE) plane and cost-eff ectiveness acceptability (CEA) Curve showing the results of 
the Monte Carlo simulations. The outcomes of the each iteration of the simulation are presented in a CE-plane. 
These results were used to determine the corresponding CEA curve. This curve shows the probability ‘PGx’ is 
cost-eff ective, compared to ‘no PGx’.
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The relative contributions to the uncertainty of the estimate of the ICER were 
explored in a sensitivity analysis. Important assumptions made, due to no or 
little availability of information, on the reduction of side effects when switching 
drugs or changing dosage were also tested in these analysis to see their influence. 
Results are presented in the Tornado diagram (Fig. 3). The base case analysis 
is represented by the vertical line. When changing the parameter into a lower- 
or a higher parameter value (tested range stated behind the parameter), this 
resulted in different values for the ICER (presented behind the horizontal bars). 
The diagram shows that particularly costs due to productivity losses had a major 
impact, and could even result in ‘PGx’ being dominant (less costs, more QALYs) 
compared to ‘no PGx’. Also, the probability of sustaining an (adverse) effect after 
treatment adjustments strongly affected the cost-utility of ‘PGx’, ranging from a 
fairly acceptable ICER (€38,000) to ICERs that are usually considered unacceptable 
(€277,000). Other important parameters that determined the potential impact 
with ‘PGx’ were related to the amount of effect that could be achieved and side 
effects prevented with ‘PGx’ compared to ‘no PGx’. If the ‘no PGX’ strategy is more 
effective and results in less side effects (high parameter value for ‘probability 
effect PM’, and low parameter value ‘probability side effects PM’), the ICERs are 
becoming unacceptable (€205,000 and €134,000 respectively), and vice versa. 
Costs of ‘PGx’ formed an important cost driver, When the costs of testing would 
decrease to €60 , ‘PGx’ could become the dominant strategy compared to ‘no PGx’.
The first scenario analysis showed that with a delayed effect of a week for ‘PGx’, the 
genotype strategy becomes not cost-effective. It even results in a ‘inferior’ result, 
which means that ‘no PGX’ is cheaper and results in more effects (ICER: ‘inferior’; 95 
percentiles: ‘inferior’ - €5,462). The second scenario showed that when productivity 
losses were not taken into account, the ICER became €121,172 (95 percentiles: 
€49,000 - €492,500) and therefore the ‘PGx’ strategy not cost-effective. 
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Figure 3. Tornado diagram showing an overview of the univariate sensitivity analyses. The diagram shows an 
overview of the univariate sensitivity analyses. In these analyses the diff erent parameters were varied on their 
uncertainty range (presented behind the parameter), to see the infl uence on the ICER. The vertical line represents 
the ICER of the base-case analysis.
33
Cost-utility of pre-emptive CYP2D6 testing in major depressive patients
2
Discussion
This study assessed the likely cost-utility of ‘PGx’ in order to optimise the current 
practice of ‘trial and error’ in antidepressant treatment in primary care. The base 
case showed that ‘PGx’ might be considered cost-effective, with an ICER of about 
€77,406 (95 percentiles: 22,500 – 377,500) per QALY gained compared to ’no PGx’. 
However, due to uncertainty regarding key model parameters, the ICER could shift 
from ‘dominant’ to unacceptable ICERs. This was especially due to information on 
the clinical utilities related to treatment changes according to a patient’s metaboliser 
status: little information was available on the reduction of side effects when 
switching drugs or changing dosage. This information is expected from the ongoing 
U-PGx study, and could reduce the uncertainty of the modelling exercise (43).
An explanation for the results of our model is that with ‘PGx’ mostly treatment for 
PM was changed. This means that this group of patients mostly determined the 
cost-utility. The majority of the population (EM, about 85%) received no treatment 
adjustments due to ‘PGx’, and therefore had no influence on the cost-utility. The 
rest (UM, about 2%) are only a small part of the population, and had no significant 
influence. Therefore, the parameters with the most influence on the ICER were 
related to the chance of side effects or effects for PM. The degree to which 
the ICER is favourable depends on the efficiency of preventing effects by ‘PGx’ 
compared to ‘no PGx’: for example in case of a higher parameter value for chance 
side effects PM after ‘PGx’, more side effects can be prevented and the ICER will 
be more favourable and vice versa. This means that in terms of costs and QALYs, 
the most important determinant is to what extent side effect can be prevented. 
Important limitations have to be taken in mind when interpreting the results, 
mainly relating to paucity of relevant evidence. A major limitation of our study is 
that we only gathered model parameters from a study by Shams et al., the only 
one study that looked at the effects of venlafaxine stratified by metaboliser class. 
This could have lead to an overestimation of our results, as it is the question if 
other antidepressants has the same strong effect with CYP2D6. We however did 
not want to create more uncertainty by also making assumptions for the other 
antidepressants. Also, when we would have assumed other effects sizes for the 
different antidepressants, the differences in effect and costs would have almost 
be the same as these changes will apply for both scenarios. Another limitation 
has to do with the fact that some studies looked at the outcomes related to a 
genetic profile, so, for instance, times of ‘switching’ or discontinuation within 
each metaboliser class (12, 19, 25, 44). However, the reason for this change in 
treatment is not always clear from the reports. Also, evidence concerning the 
effectiveness (remission) made no distinction between metaboliser classes and 
showed more ‘general’ effect measures (like ‘response’), or changes on certain 
scales (8, 34, 45, 46). Second, the clinical utility of ‘PGx‘ is mostly unknown. From 
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the available evidence, it is not possible to trace what the consequences might 
be of adjusting treatment by ‘PGx’. This means that this could have led to under- 
or over adjustment of the consequences of this strategy. Third, in our base case 
analysis we assumed no delayed effect due to genetic screening, receiving the 
test result and subsequently adjusting treatment. However, genetic information 
is not always directly available, especially in primary care (24). This assumption 
could have resulted in an overestimation of the cost-effectiveness, as our scenario 
analysis show that genetic screening is not cost-effective when assuming a 
delayed effect. Another limitation of this study was that only one gene / drug class 
interaction was investigated. As the CYP2D6 gene interacts with more drugs than 
only antidepressants (e.g. tamoxifen and beta blockers (22)), the assumptions 
made on the benefits from this ‘PGx’ are likely to be too conservative. 
This study provides a model to determine the cost-utility of pre-emptive ‘PGx’ in 
starting antidepressants that can be generalised for Western Europe, as clinical 
practice is comparable. Our sensitivity analysis showed the influence of important 
parameters on the ICER, like the prevalences of genotypes or disease severity. This 
makes it possible to see the influences if an important parameter would differ within a 
country. Also we showed the influence of prices of testing. This parameter is important 
as the prices differ among countries and will probably change in the future (47).
From our study we cannot unequivocally conclude that ‘PGx’ can be a cost-effective 
strategy in starting treatment of depressive patients in primary care, as this is 
surrounded with a great amount of uncertainty (±48% chance being cost-effective at 
WTP of €80,000/QALY). This uncertainty makes it difficult to give a definitive answer to 
our research question, and therefore information from ongoing studies is necessary 
to update the parameter values involved and validate our results in the next few 
years. Our model and outcomes give however a great amount of information of which 
gaps in knowledge and evidence needs to be explored to reduce these uncertainties. 
Finally, although patients’ genetic properties could be taken into account, other 
diagnostics, such as therapeutic drug monitoring, psychosocial factors, etc., remains 
necessary to optimise treatment as ‘PGx’ still misses a part of the patients with a poor 
metabolizer status or that are still not responding to treatment (48, 49). 
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Alcohol use disorders (AUD) are a major contributor to the global burden of disease, 
and have huge societal impact. Some studies show that AUD patients carrying the 
G-allele of the OPRM1 variant c.118A>G respond better to naltrexone, resulting 
in reduced relapse rates compared to carriers of the AA genotype. Genotype-
guided treatment allocation of these patients carrying a G-allele to naltrexone 
could potentially improve treatment outcome. However, cost-effectiveness of 
this strategy should be investigated before considering clinical implementation. 
We therefore evaluated costs and Quality-Adjusted Life-Years (QALYs), using 
a modelling approach, from an European perspective, of genotype-guided 
treatment allocation (G-allele carriers receiving naltrexone; AA homozygotes 
acamprosate or naltrexone) compared to standard care (random treatment 
allocation to acamprosate or naltrexone), by using a Markov model. Genotype-
guided treatment allocation resulted in incremental costs of EUR 66 (95% CI: -28 
to 149) and incremental effects of 0.005 QALYs (95% CI: 0.000 to 0.011) per patient 
(Incremental cost-effectiveness ratio of EUR 13,350 per QALY). Sensitivity analyses 
showed that the risk ratio to relapse after treatment allocation had the largest 
impact on the cost-effectiveness. Depending on the willingness to pay for a gain 
of one QALY, probabilities that the intervention is cost-effective varies between 6 
and 79%. In conclusion, pharmacogenetic treatment allocation of AUD patients 
to naltrexone, based on OPRM1 genotype, can be a cost-effective strategy, and 
could have potential individual and societal benefit. However, more evidence 
on the impact of genotype-guided treatment allocation on relapse is needed 
to substantiate these conclusions, as there is contradictory evidence about the 
effectiveness of OPRM1 genotyping. 
 
Key words: Cost-Effectiveness; Pharmacogenetics; Alcohol Use Disorder;  
Naltrexone; Acamprosate
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Introduction
Alcohol use disorders (AUD) are major contributors to the global burden of disease, 
with a net contribution of 3.8% to all global deaths and 4.6% to all global disability-
adjusted life years (DALYs; measure for burden of disease) (1). Worldwide, 
this corresponds to 2·2 million deaths and 70 billion DALYs lost to alcohol-use 
disorders a year (2). This is mainly caused by alcohol-induced physical adversities, 
like liver disease, pancreatitis, several types of cancer, fetal alcohol syndrome, 
and neuropsychiatric disorders (3). This burden of disease comes with substantial 
societal impact. In Europe, an estimated 14.6 million people are affected by AUD, 
corresponding to total cost of about 62.3 billion Euros a year (4).
Evidence-based treatment of AUD includes psychological and pharmacological 
interventions (5, 6). Naltrexone and acamprosate are the most effective 
pharmacological interventions currently available for AUD treatment (5, 7). It has 
been shown that naltrexone significantly reduces the number of drinking days and 
levels of alcohol craving (8), with a number needed to treat to prevent a relapse 
into heavy drinking of 9 (9). Comparably, the anti-craving drug acamprosate has 
been shown to reduce the risk of relapse into any drinking (10), with a number 
needed to treat to prevent a relapse of 8 (9). In clinical practice, naltrexone or 
acamprosate are both considered first-choice pharmacological treatments, and 
are prescribed with similar frequencies (5, 6, 10, 11). 
Despite their proven potential effectiveness, less than 20% of treated AUD 
patients receive anti-craving medication (12). This might be due to the side effects 
of naltrexone and acamprosate, such as nausea, headache, dizziness, anxiety and 
diarrhea (5, 8, 10, 13), and medication contra-indications: kidney failure for both 
naltrexone and acamprosate; liver issues for naltrexone (13). Hence, healthcare 
professionals are sometimes skeptical about the role of pharmacotherapy in the 
treatment of addictive behaviors (14). Improving patient-treatment matching, 
by selecting those patients with higher chances of good response might be an 
important step to improve the implementation of pharmacotherapy and treatment 
outcome for AUD. 
The genetic background of a patient is one of the factors underlying differential 
responses to pharmacological treatment (“pharmacogenetics”) (15-17). Meta-
analysis showed that a genetic variant (single nucleotide polymorphism) in 
the OPRM1 gene (rs1799971), resulting in a change of A to G at position 118, is 
associated with increased effectiveness of naltrexone. AUD carriers of a G-allele 
(15% of the Caucasian population (18, 19)) have 2 times lower relapse rates 
compared to persons with the AA genotype, when treated with naltrexone (15, 
20, 21). Prescription of naltrexone instead of acamprosate for all AUD carriers of 
a G-allele could improve the overall treatment effectiveness, by preventing more 
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relapses and therefore reducing costs associated with AUD. However, a recent 
study did not support previous findings on OPRM1 genotype-guided treatment 
allocation in AUD patients (22). 
Given the substantial economic costs associated with AUD and relapse, systematic 
screening for OPRM1 genotype could however be economically attractive, even 
when there is a small effect. However, it is unknown whether the potential cost-
savings by potential optimizing treatment for part of the AUD population outweigh 
the screening costs of genetic testing of the whole AUD population. Such cost-
effectiveness analyses of genotype-guided treatment allocation are currently 
lacking (23). However, given the contradictory evidence concerning the increased 
effectiveness of naltrexone in OPRM1 G-allele carriers compared to A-allele 
homozygotes, it is highly relevant to evaluate at which threshold of increased 
effectiveness OPRM1 genotyping becomes cost-effective. 
The aims of this study are to evaluate 1) cost-effectiveness, by using a modelling 
approach based on existing data, of OPRM1 genotype-guided treatment allocation 
of naltrexone to G-allele carrying AUD patients, compared to random (non-
genotype guided) treatment allocation to pharmacological treatment with 
naltrexone or acamprosate, and 2) at which threshold of added effectiveness 
OPRM1 genotype screening is cost-effective, from an European perspective. 
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A Markov model was built to compare the 2 diff erent treatment strategies (genotype-
guided treatment allocation, versus random treatment). This Markov model is 
used to model diff erent treatment options and outcomes over time by using the 
probabilities that these events or outcomes occur within a certain time range (Fig. 1 
for an outline of the model) (24). This analysis applied a societal perspective, taking 
all relevant societal costs into account. The 2 strategies were: (1) to screen all patients 
for the OPRM1 c.118A>G variant, which guided treatment allocation (G-allele carriers 
receiving naltrexone, AA homozygotes receiving random naltrexone or acamprosate 
(resembling current practice as much as possible)), and (2) to randomly assign 
treatment of naltrexone or acamprosate to all patients (non-genotype guided). After 
the patients received one of the treatment options depending on the strategy, they 
had a certain chance to relapse or not. The relapse state was an absorption state, 
indicating that a patient stayed in this health state for the rest of the time horizon. 
The cycle length in both strategies for the risk of relapse or not was 1 month, with 
a maximum time horizon of the analysis of 12 months. The analyses (including 
sensitivity analysis) were performed in Microsoft Offi  ce Excel 2007. 
Figure 1. Structure of the Markov model. In this model, the strategy of OPRM1 screening was compared to 
no screening. In the screening strategy (1; in dark gray), alcohol-dependent patients with a G-allele received 
naltrexone, and AA homozygotes randomly received either acamprosate or naltrexone. In the no screening 
strategy (2; in white), treatment allocation was non-genotype guided, and therefore patients randomly received 




The parameters used for the analyses, are shown in Table 1. For each parameter a 
summary value and uncertainty range were searched. The summary values were 
used in the base-case analysis, and the uncertainty ranges in the sensitivity analysis. 
The prevalence estimation of the G-allele and AA genotype was based on several 
population studies (18, 19). The estimation of the risk of relapse after treatment 
with naltrexone or acamprosate was based on a recent network meta-analyses 
on the effectiveness of pharmacological interventions on AUD, performed as part 
of a National Institute of Health and Care and Excellence (NICE) guideline for AUD 
(25). Both treatments are considered equally effective as shown by the credible 
interval of the network meta-analyses. Therefore, the same relapse chance was 
considered for both drugs. The chance of no relapse was complementary to the 
chance of relapse, counting up to 100%. 
The risk of relapse in G-allele carriers when treated with naltrexone was based on 
recent meta-analysis of the effectiveness of naltrexone treatment in AUD G-allele 
carries and persons with the AA genotype (15). This risk ratio was multiplied with 
the general relapse chance with acamprosate/naltrexone to determine the relapse 
chance in G-allele carriers treated with naltrexone. 
The utility values of the events of “relapse” and “no relapse“ were based on the same 
NICE guideline for AUD (25). A utility (expression of the health-related quality of life) 
represents the preference for a certain health state, where 1 represents perfect 
health and 0 represents death, and is used to calculate Quality-Adjusted Life-Years 
(QALYs) (see Analysis) (24, 26). The resources used in case of ‘no relapse’ (including 
all healthcare costs) were also based on this guideline, and transformed to the 
Dutch situation by multiplying these resources with Dutch standard cost prices (27). 
The costs of the event “relapse” was based on a recent report about Dutch addiction 
care (“Verslavingszorg in beeld – alcohol en drugs” (28)), and updated with price 
indices to 2015. These costs included all societal costs (including healthcare, non-
healthcare and indirect costs) associated with alcohol use (29). The costs for genetic 
screening were based on current prices provided by the Department of Human 
Genetics of the Radboudumc Nijmegen. As costs of naltrexone and acamprosate 
are comparable, these were not included in the analysis. 
47
Cost-Effectiveness of OPRM1 Genotyping in AUD Patients
3





Probability of G-allele carriers in Caucasians 0.150 0.100–0.200 [18, 19]
Probability of AA homozygous in Caucasians 0.850 0.800–0.900 [18, 19]
Relapse chance with acamprosate/naltrexone treatment 0.132 0.040–0.479 [25]
No relapse chance with acamprosate/naltrexone 
treatment
0.868 0.521–0.960 [25]
Risk ratio to relapse when G-allele carriers treated with
naltrexone (screening strategy) 0.508 0.273–0.943 [15]
Utility of relapse 0.540 0.390–0.670 [25]
Utility of no relapse event 0.860 0.830–0.890 [25]
Costs of successful AUD treatment (no relapse) per 
month
EUR 82.50 EUR 40.00–
125.00
[25]
Costs of failed AD treatment (relapse) per month EUR 533 EUR 333–583 [28]




AUD, alcohol use disorders.
Analysis
At first we did a base-case analysis, where the parameters, as presented in Table 1, 
were entered into the model. This base-case analysis was performed with the data 
of the meta-analyses. A Monte Carlo simulation with 5000 iterations was performed 
(24, 26, 30). In these iterations, parameter uncertainty of all parameters was taken 
into account at the same time, by randomly choosing a value from their distribution 
based on the uncertainty ranges of Table 1. In economic evaluations we use beta 
distributions for probability rates and utilities, as these values can vary between 
0 and 1, lognormal distribution for risk ratios, as the confidence limits values are 
calculated on a log-scale, and gamma distributions for costs, as these values are 
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always non-negative. QALYs were calculated by multiplying the utility value of the 
health state (“relapse” or “no relapse”) with the time spent in that health state (24). 
Subsequently, for each iteration of the Monte Carlo simulation an incremental 
cost-effectiveness ratio (ICER) was calculated, based on the comparison between 
screening and no screening. The results were plotted in a cost-effectiveness plane, 
and were used to draw a cost-effectiveness acceptability (CEA) curve, which shows 
the probability that screening is cost-effective, compared to no screening, for 
different willingness to pay (WTP) thresholds (24, 26). These WTP thresholds indicate 
the maximum amount of money society is willing to pay to gain one unit of effect 
(i.e. QALYs). Subsequently, we did univariate sensitivity analyses to investigate the 
influence of variation per parameter within an uncertainty range. These analyses 
were done to show which parameter mostly determines cost-effectiveness. The 
results of these analyses were summarized in a Tornado diagram (Fig. 3), which 
shows the maximum impact of the extremes of the uncertainty ranges on the 
incremental net monetary benefit (iNMB) for each parameter. The iNMB shows 
the value of screening in monetary terms, compared to random treatment, by 
re-scaling the QALY gain into monetary value using the amount of money society 
is willing to pay for this unit of effect. This value is calculated as: iNMB=WTP * 
incremental QALYs-incremental costs. For these calculations a WTP of EUR 80,000/
QALY was considered, which is often considered as the maximum society is willing 
to pay to gain one QALY. A positive iNMB indicates that the intervention is cost-
effective, and vice versa. 
Eventually, we performed a threshold analyses for the risk of relapse in G-allele 
carriers using naltrexone, as the study of Oslin et al. (22) showed no-effect of 
OPRM1 genotyping. With this threshold analysis, the minimal added effectiveness 
of genotype-based treatment allocation at which screening is cost-effective was 
determined. This was calculated by varying the relative risk ratio for relapse in the 
genotype-based treatment allocation between 0 and 1 and then evaluate the ICER 
at each risk ratio.
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Results
The results of the simulation of the base-case shows that treatment allocation of 
naltrexone versus acamprosate based on OPRM1 genotyping was more expensive 
with EUR 66.22 per patient (95% CI:-28 to 149), but also more effective with 0.005 
QALYs (95% CI: 0.000-0.011) gained per patient, compared to non-genotype 
guided treatment allocation of AUD patients (Table 2). This results in an ICER of 
EUR 13,349.71 (95% CI: 442,000 to dominant) per QALY. 
The results of the simulation are presented in a cost-effectiveness plane in Figure 
2a, with corresponding CEA curve in Figure 2b. The curve shows the probability 
of cost-effectiveness for different WTP levels. At a WTP of EUR 0, screening has 
a probability of 6% being “dominant”, indicating that in 6% of the iterations 
screening resulted in increased effectiveness (increased QALYs) and cost savings, 
compared to no screening (south-east corner of the cost-effectiveness plane). 
With a WTP of EUR 80,000 per increased QALY, often considered as the maximum 
people are willing to pay for a QALY, screening for the genetic variant in OPRM1 
and adjusting treatment accordingly has a probability of 75% of being the most 
cost-effective strategy, corresponding to 75% of the iterations lying below this 
threshold (represented by the line in Fig. 2a). It can also been seen in the CEA-
curve (Fig. 2b) that this probability slowly rises (up to maximum 79%) when the 
WTP becomes higher. 
Table 2. Costs and effects of the strategies of screening and no screening











OPRM1 screening EUR 3,610.66   
(EUR 1,166 - EUR 5,681)
EUR 66.22   




0.005   
(0.000 - 0.011)
No OPRM1 screening EUR 3,544.44   
(EUR 1,024 - EUR 5,629)
0.709   
(0.567 - 0.862)
Costs and QALY’s are presented as means with 95% CI, resulting from Monte Carlo simulation with 5000 
iterations. 
QALY; quality adjusted life year
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Figure 2. A, B Cost-effectiveness plane and cost-effectiveness acceptability (CEA) curve. Outcomes of the 
simulation presented in a cost-effectiveness plane, with corresponding CEA curve. This curve shows that 
the probability OPRM1-guided treatment allocation is cost-effective, compared to no screening for different 
willingness to pay thresholds.
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Univariate Sensitivity Analysis
The results of the univariate sensitivity analyses are presented as a Tornado 
diagram in Figure 3. This diagram shows the effect of changing a parameter 
(tested ranges are presented behind each parameter) on the iNMB. The risk ratio 
to relapse in G-allele carriers treated with naltrexone has the largest effect on 
the iNMB, ranging from not cost-effective at -EUR 105 to cost-effective at EUR 
684, when changing this parameter to a lower or higher level than in the initial 
analysis. Furthermore, for all other parameter values the iNMB stays positive, 
ranging between about EUR 170 and 516. These positive iNMBs show that for 
each parameter value screening stays cost-effective. 
Figure 3. Tornado diagram, summarizing the results of the univariate sensitivity analyses. In these analyses the 
presented parameter estimates vary within an uncertainty range (presented behind each parameter), in order to 
see the influence on the incremental Net Monetary Benefit (iNMB) for a Willingness To Pay of EUR 80,000/QALY 
(vertical line representing the iNMB of the base-case analysis).
Threshold analysis
The results of the threshold analysis are presented in Figure 4. In this Figure it can 
be seen that at a risk ratio ≤0.81 screening is cost-effective with a WTP of EUR 
80,000 / QALY. When the risk ratio is ≤0.25 screening becomes the “dominant” 




Figure 4. Diagram summarizing the results of the threshold analyses. This figure shows the impact of the risk to 
relapse in G-allele carriers using naltrexone on the incremental cost-effectiveness ratio (ICER), and at which risk 
ratio screening is cost-effective at a Willingness To Pay (WTP) of EUR 80,000/QALY. The solid line indicates the 
ICER for each value of the risk ratio. 
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Discussion
This is the first study investigating cost-effectiveness of OPRM1 genotype-guided 
treatment allocation of naltrexone in AUD patients. In our base-case analysis, 
assuming an effect of the OPRM1 genotype, we showed that OPRM1 screening can 
be cost-effective. However, these results need to be interpreted very carefully as 
recent evidence did not confirm prior data on OPRM1 pharmacogenetics in AUD 
(22). On average, the genotype strategy is slightly more expensive, but also slightly 
more effective compared to no genotyping strategy. This results in an ICER of 
approximately EUR 13,350 per QALY, which is generally considered acceptable 
(31). Depending on how much decision makers are willing to pay for a QALY, the 
probability that OPRM1 screening is the preferred strategy ranges between 6 and 
79%. The univariate sensitivity analysis showed that the ICER is mostly determined 
by the risk of relapse in AUD G-allele carriers treated with naltrexone. Threshold 
analysis showed that when the risk ratio of relapse between naltrexone in G-allele 
carriers versus A-allele homozygotes was smaller than 0.82, screening was cost-
effective at a WTP of EUR 80,000 / QALY, and at a risk ratio smaller than 0.25 
screening was the dominant strategy. When looking at the CI of the relative risk 
ratio for relapse in the G-allele carriers versus AA homozygotes in the meta-
analysis of 0.273 – 0.943, this threshold seems reachable, but the study of Oslin et 
al. (22) could not confirm this. To give a definite answer on the cost-effectiveness 
of OPRM1 genotyping, more studies are needed to determine the effectiveness of 
naltrexone in AUD G-allele carriers compared to AA homozygotes.
The percentage of G-allele carriers in the population also had a major impact on 
the sensitivity analysis. Higher G-allele frequencies increase the cost-effectiveness 
of OPRM1-guided treatment allocation. In Asian populations the percentage of 
G allele carriers is much higher (about 60%) than in Caucasian (about 15%) and 
African populations (about 1%) (19, 32). Cost-effectiveness of OPRM1 genotype 
guided treatment allocation in AUD might therefore be more cost-effective in Asian 
regions, while less cost-effective in African regions, as compared to Caucasian 
populations (19, 33).
Finally, the cost of genotyping, which probably will decrease in the coming years, 
influenced cost-effectiveness (34, 35). In our model, a price below EUR 129 per genetic 
screening, is associated with increased effectiveness at lower costs (“dominant”), 
indicating that OPRM1 genotype-guided treatment allocation would be the preferred 
strategy. Importantly, cost-effectiveness will also increase with increasing costs 
related to AUD and relapse. Though the costs of relapse have no major impact on the 
cost-effectiveness, our cost estimation of about EUR 6,402 per year is a conservative 
estimation of the costs (4, 36, 37). Literature on AUD-related costs is however scarce 
and sometimes outdated. Future data on the costs of AUD might shed new light on 
cost-effectiveness of OPRM1 genotype-guided treatment allocation in AUD. 
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Economic evaluations, like the present cost-effectiveness analysis, are widely used 
to inform policy makers about which treatment innovations should be reimbursed 
or promoted (24, 26). Such evaluations have become increasingly important, given 
the rising healthcare costs worldwide. Information about the potential benefits 
of an innovation for prevention, diagnosis or treatment at acceptable costs is 
critical to keep healthcare budgets sustainable. Cost-effectiveness studies of 
pharmacological interventions for AUD have shown that pharmacotherapy for 
AUD is highly cost-effective (38). Adding pharmacogenetic treatment allocation 
to the treatment algorithm is associated with increased costs. In this study we 
showed under which conditions this intervention could be of potential societal 
value in the treatment of AUD patients. This evidence is of great value, as evidence 
surrounding the most important parameter, the increased effectiveness of 
naltrexone after pharmacogenetic matching is still contradictory. As AUD-related 
costs are estimated at billions of Euros worldwide, a relative simple intervention 
with even a small effect to improve pharmacological treatment outcome, like 
genetic screening, could prevent tremendous harm and societal costs (4).
Though the potential clinical utility of genetic screening seems promising, 
integration of genetic services into clinical practice is not fully supported by all 
healthcare professionals (34). In a recent meta-analysis four major barriers for 
implementation of genotype-guided treatment allocation were identified: lack of 
knowledge/skills, lack of infrastructure, ethical, legal and social issues and lack of 
evidence. Barriers related to insufficient knowledge and skills are most frequently 
cited in literature (39). This warrants education and training of physicians on 
genetics and genetic testing to develop pharmacogenetic competencies required 
in clinical practice. Furthermore, system-level barriers (lack of access to genetic 
services, time constraints) are noted as significant impediments to primary-
care providers integrating genetics into their practice (39). Development of 
easy accessible genetic services and coverage by health insurance could greatly 
contribute to the implementation of genotype-guided treatment allocation in clinical 
practice. Importantly, personalizing pharmacotherapy could impact on potential 
motivational aspects in AUD patients. This could increase pharmacotherapy 
coverage and treatment adherence in AUD patients and therefore have a huge 
public health impact. 
Finally, barriers related to scientific evidence of genetics services are identified (39). 
The results of the cost-effectiveness analysis presented here do support the need 
for further development of strategies to implement genotype-guided treatment 
allocation for AUD patients. In future, recommendations on genotype-guided 
treatment allocation should be incorporated in treatment guidelines, including 
those on AUD. For example, OPRM1 genotype-guided treatment allocation is 
not mentioned in current guidelines (5, 6, 25, 40). Cost-effectiveness analyses of 
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pharmacogenetic strategies are therefore urgently needed, in order to further 
optimize clinical practice.
Moreover, several other potential candidate genes for genotype-guided treatment 
allocation in AUD have been suggested. For example, potential candidates 
possibly related to the effectiveness of acamprosate are the DRD2, GABRA6, 
GABRB2, and GATA4 genotypes (23, 41). If patient-treatment matching could be 
further optimized by adding a list of genes predictive for treatment response to 
a range of medications, cost-effectiveness could increase even more. As such, 
future evidence on genotype-guided treatment allocation in AUD could further 
optimize the treatment of AUD patients.
The presented model has several assumptions that need to be taken into account 
when interpreting the results of this study. First, the risk-value used in the base-
case scenario was based on a recent meta-analysis evaluating the efficacy of 
naltrexone in AUD G-allele carriers versus AA homozygotes (15). Recent evidence 
did not confirm the conclusions of this meta-analysis (22). Our findings provide 
an indication what added effectiveness in G-allele carriers minimally needs to be 
achieved to let OPRM1 screening be the preferable strategy in AUD treatment from 
a cost-effectiveness perspective.
Next, in our study both AA homozygotes and the non-genotyping arm received 
acamprosate in 50% of cases. There is currently no evidence that in AA homozygotes 
acamprosate is actually better than naltrexone. Scientific evidence mainly focused 
on the association between naltrexone efficacy and the OPRM1 G-allele. In general, 
there appears to be no difference in between acamprosate and naltrexone 
in controlling alcohol consumption, as shown by Jonas et al. (11). Studies on 
efficacy of acamprosate in AA homozygotes are highly needed. To minimize the 
risk of overestimation of cost-effectiveness, we applied a conservative approach 
assuming similar effectiveness for naltrexone and acamprosate. We also wanted 
the control condition to resemble the current practice as much as possible, in 
order to show potential benefit compared to current practice. Therefore, we 
chose 50% exposure to acamprosate in the AA-homozygous group and in the non-
genotyping arm.
In our model treatment allocation is unchanged over the one-year iteration period. 
It has to be acknowledged that current treatment guidelines for AUD do not mention 
a strict evaluation window for (pharmacological) interventions, unlike for example 
for antidepressant medication (42). Moreover, in clinical practice a relapse is not 
necessarily an indication that the medication is ineffective, or a common reason 
for medication switch. On the contrary, in case of relapse it cannot be ruled out 
that the medication provided is ineffective, and patients should better switch to 
56
CHAPTER 3
other potentially more effective medications. If this were true, the current model 
might overestimate cost-effectiveness of pharmacogenetic treatment allocation 
of naltrexone in AUD.
The estimated probabilities of relapse with acamprosate or naltrexone treatment 
should be interpreted carefully. We assumed that both drugs are equally effective. 
However in clinical practice their effectiveness varies highly between patients 
and across studies (10, 11). If acamprosate happens to be more effective than 
naltrexone, the current results overestimate the cost-effectiveness of OPRM1 
genotype-guided treatment allocation, or vice versa. For our effectiveness 
parameters we used a meta-analyses from a NICE guideline, which had 2 major 
limitations (25). First, the time horizon of the model in this study was 12 months. 
The meta-analyses on the effectiveness of naltrexone and acamprosate in AUD 
included only studies with a time horizon of 3-6 months. Since in clinical practice 
naltrexone and acamprosate are commonly prescribed for more than 3-6 
months, results were inferred to 1-year outcome (38). The extrapolation of the 
data over a 12-month period, could have introduced uncertainty in our model. 
If the effectiveness of naltrexone or acamprosate declines after 3 or 6 months, 
this could have led to an overestimation of our results. Second, in all trials used 
in the meta-analyses, pharmacotherapy was used as an adjunct to psychological 
therapies. The authors of these analyses assumed that any differences in effect 
were related to pharmacotherapy, as opposed to the psychological therapies. This 
assumption could have also led to an overestimation of our results, as the effects 
of naltrexone or acamprosate could have been limited. 
Also, some studies do suggest that acamprosate might be more effective in the 
long-term, compared to naltrexone (5). In contrast, several other studies favor 
efficacy of naltrexone in the treatment of AUD (9, 10, 16, 43). If the effectiveness of 
naltrexone indeed declines after 6 months, this could lead to an overestimation of 
the cost-effectiveness in our model. In addition, it has to be taken into account that 
European and US-based trials in AUD are often incomparable, given the common 
differences in patient characteristics in these studies, including differences in 
AUD severity and medication effectiveness (10, 44). However, in our sensitivity 
analyses, we showed that the probability to relapse with one of the 2 drugs has 
limited effect on our results. 
This study focused on the return to heavy drinking as definition of relapse, 
assuming that this is most relevant in terms of costs of relapse. It has been 
suggested that naltrexone is more effective in reducing the total amount of 
alcohol consumption, whereas acamprosate may be more effective in obtaining 
complete abstinence (11). Results of the cost-effectiveness analysis do depend on 
the definition of relapse. For example, including any level of drinking as outcome 
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(instead of heavy drinking) might increase or decrease the cost-effectiveness. For 
running cost-effectiveness analyses the outcome measure should be comparable 
between both arms and should be translated into monetary costs. The only 
available cost estimates do not specify specific drinking levels. Therefore, we 
decided to compare relapse versus abstinence, though this does not fully match 
the current evidence on the efficacy of naltrexone versus acamprosate. 
Acamprosate was chosen as an alternative for naltrexone in the pharmacological 
treatment of AUD. There are several other effective drugs available for AUD 
treatment, including for instance disulfiram, baclofen and topiramate (13, 43). 
Some studies show that disulfiram might be less effective, compared to naltrexone 
and acamprosate (11). Evidence for baclofen and topiramate in AUD is still limited, 
with their use in AUD being mainly off-label (5, 38, 45). Moreover, pharmacotherapy 
is often combined with psychosocial interventions, which might influence the cost-
effectiveness. In future, it may be needed for additional treatment options in cost-
effectiveness analysis as well. 
In conclusion, our cost-effectiveness analysis showed that genotype-guided 
treatment allocation to naltrexone in patients with AUD can be a cost-effective 
strategy, compared to the random (non-genotype guided) allocation of 
acamprosate or naltrexone. However, uncertainty surrounds the evidence for 
pharmacogenetic treatment allocation of naltrexone in AUD, and supported 
by our sensitivity analyses, more studies on the effectiveness of naltrexone in 
G-allele carriers are needed to affirm the cost-effectiveness of genotype-guided 
treatment allocation in AUD. This intervention could however be of potential value 
in the treatment of AUD patients at acceptable costs, if evidence of increased 
effectiveness is confirmed and costs of genotyping decrease. 
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Background and Aims: Decreased thiopurine S-methyltransferase (TPMT) 
enzyme activity increases the risk of haematological adverse drug reactions (ADRs) 
in patients treated with thiopurines. Clinical studies have shown that in patients 
with inflammatory bowel disease (IBD), pharmacogenetic TPMT-guided thiopurine 
treatment reduces this risk of ADRs. The aim of this study was to investigate, 
whether this intervention impacts on healthcare costs and/or quality of life. 
Methods: An a priori defined cost-effectiveness analysis was conducted in the 
Thiopurine response Optimization by Pharmacogenetic testing in Inflammatory 
bowel disease Clinics (TOPIC) trial, a randomized controlled trial performed in 
30 Dutch hospitals. Patients diagnosed with IBD (age ≥18 years) were randomly 
assigned to the intervention (i.e. pre-treatment genotyping) or control group. 
Total costs in terms of volumes of care, and effects in quality-adjusted life years 
(QALYs), based on EuroQol-5D3L utility scores, were measured for 20 weeks. Mean 
incremental cost savings and QALYs with confidence intervals were calculated 
using non-parametric bootstrapping with 1000 replications. 
Results: The intervention group consisted of 381 patients and the control group 
347 patients. The mean incremental cost savings were €52 per patient (95% 
percentiles -682, 569). Mean incremental QALYs were 0.001 (95% percentiles: 
-0.009, 0.010). Sensitivity analysis showed that the results were robust for 
potential change in costs of screening, costs of biological and costs associated 
with productivity loss. 
Conclusions: Genotype-guided thiopurine treatment in IBD patients reduced the 
risk of ADRs among patients carrying a TPMT variant, without increasing overall 
healthcare costs and resulting in comparable quality of life, as compared to 
standard treatment. 
Keywords 
inflammatory bowel disease; thiopurines; health economics; 
65
Cost-effectiveness of  TMPT-guided drug dosing
4
Introduction
Treatment of inflammatory bowel disease (IBD; Crohn’s disease (CD) and ulcerative 
colitis (UC)) with thiopurines is very effective in maintaining remission in the majority 
of patients (1). However, approximately 20% of the patients develop adverse drug 
reactions (ADRs), which may lead to early treatment withdrawal (2, 3). 
Thiopurine S-methyltransferase (TPMT) is a key enzyme in the conversion of 
thiopurines to the active metabolite 6-thioguanine (4, 5). Different studies have 
shown that patients with a decreased TPMT enzyme activity are prone to developing 
haematological ADRs while being treated with thiopurines (5). Some of these 
haematological ADRs can be prevented by personalized thiopurine dosing based on 
(predicted) TPMT enzyme activity. This activity can be predicted prior to treatment by 
a pharmacogenetic test or can be determined by direct enzyme activity measurement 
or by metabolite measurements during treatment (1, 6). A clinical study showed that 
personalized thiopurine dosing based on pharmacogenetic TPMT testing reduces the 
occurrence of haematological ADRs. Our randomized controlled trial, the Thiopurine 
response Optimization by Pharmacogenetic testing in Inflammatory bowel disease 
Clinics (TOPIC) trial, showed that there was no overall difference in proportions of 
patients with a haematological ADRs between the intervention (7.2%) and control 
group (7.8%).  However, the small group of patients with a genetic variant in TPMT 
receiving a specified reduced thiopurine starting dose had a 10-fold reduction in 
haematological ADRs (2.6%), compared to variant carriers, who did not receive 
dose reduction (22.9%) (7). To treat patients according to their TPMT genotype, 
every individual patient starting thiopurine treatment needs to be genetically 
tested, generating additional costs, compared to no genotyping. On the other hand, 
personalized dosing reduces the risk of haematological ADRs and might thus reduce 
healthcare costs related to hospitalization, patient contacts, and overall medication 
use, as well as societal costs in the form of productivity loss. An earlier prospective 
cost-effectiveness analysis, the TARGET-study, investigated a range of inflammatory 
diseases (the majority being IBD patients (85%)) and performed the analysis from 
a healthcare perspective (only healthcare-related costs were included) (8, 9). This 
study showed that genotyping could be a cost-effective strategy, although this was 
not statically significant. Other cost-effectiveness studies of pharmacogenetic TPMT 
testing before thiopurine treatment made use of cost-effectiveness modelling, but 
nonetheless indicated that this intervention could be cost-effective or resulted in cost 
savings (10-12). However, because in our TOPIC trial only the small group of patients 
with the TPMT variant showed a reduction in haematological ADRs, the question 
remained regarding whether pharmacogenetic testing was truly cost-effective. 
This study aimed to investigate, from a societal perspective, the differences in costs 
and quality of life between a personalized thiopurine dosing strategy based on pre-




Study design and participants
This cost-effectiveness analysis was a priori defined in the study protocol, and data 
on costs and quality-adjusted life years (QALY) data were collected as part of the 
TOPIC trial. The TOPIC trial was a randomized controlled trial (intention to treat 
(ITT)), including patients with a diagnosis of IBD (age ≥ 18 years) from 30 Dutch 
hospitals from October 2007 until December 2010. After written informed consent, 
patients were randomly assigned to personalized thiopurine dosing based on pre-
treatment TPMT genotyping for three common genetic variants (intervention), 
TPMT*2, TPMT*3A, and TPMT*3C, or standard dosing with no genotyping (control). 
The (block) randomization was based upon a computer-generated schedule per 
participating centre (block size of 4); patients and gastroenterologists were blinded 
for this randomization. The study was approved by the local ethics committee 
(CMO region Arnhem – Nijmegen; protocol number: 13171) and by institutional 
ethics committees, and registered at clinicaltrials.gov: NCT00521950. More details 
of the study design and rationale are described elsewhere (7).
Procedures
Patients in the control group received standard treatment according to IBD 
guidelines (2–2.5 mg/kg/day azathioprine or 1–1.5 mg/kg/day 6-mercaptopurine). 
Patients in the intervention group with a genetic variant in TPMT received 50% 
(heterozygotes) or 0-10% (homozygotes) of the standard thiopurine dose according 
to pharmacogenetic dose recommendations of the Dutch Pharmacogenetics 
Working Group (13). Patients without a genetic variant received standard 
treatment as in the control group. For each patient, a letter with a dose advice was 
sent to the gastroenterologist. If an adverse event occurred, gastroenterologists 
were allowed to change dose or stop treatment with thiopurines. 
Outcomes
Costs in terms of volumes of care and quality of life are the outcomes of interest 
for this cost-effectiveness analysis. The primary outcome of the TOPIC trial was the 
development of haematological ADRs and is reported elsewhere (7). Standardized 
case record forms were used to collect data on all (clinical) consultations, diagnostic 
procedures, and hospital admissions. Medication use (type, frequency, dose) was 
based on patient records, and disease-related absence from work was measured 
with a patient diary. The Dutch Cost Manual (part of the guideline for economic 
evaluations) was used to determine standardized cost prices for consultations and 
productivity losses (14). Cost prices for medication, diagnostic procedures, and 
hospital admissions were based on the Dutch national tariffs (15, 16). Details on 
the cost prices are summarized in the Supplementary Table 1. The base year for 
all prices was 2016, and therefore cost prices were updated with Dutch consumer 
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price indices when necessary (17). Discounting was not applied because of the 
short time horizon of only 20 weeks for this study. 
Quality of life was measured with the EuroQol-5D3L (EQ5D-3L) questionnaire at 
week 0 and 20, and utilities were calculated with Dutch tariffs for the EQ5D-3L (18). 
QALYs were calculated based on the area under the curve between the two time 
points. If one of the time points of the EQ5D-3L was missing, single imputation of 
this value was performed. This was done by randomly picking a value from the 
beta distribution, based on the observed data in the remaining patients at that 
time point (19). 
Statistical analysis
Differences between the intervention and control group were evaluated for 
baseline characteristics and the specific cost components after 20 weeks using 
Pearson’s χ2 test, Fisher’s exact test, Student’s t test, the Mann-Whitney U test, or 
an independent sample Kruskal-Wallis test, as appropriate. 
Cost-effectiveness analysis
Costs and QALYs from a societal perspective (all costs relevant for society, 
including productivity losses) were calculated for the two groups (intervention 
and control) for the follow-up period of 20 weeks. Comparing the intervention 
and control groups, an incremental cost effectiveness ratio (ICER) per patient was 
calculated by dividing the incremental costs by the incremental QALYs. Confidence 
intervals around the ICER were calculated by using non-parametric bootstrapping 
with 1000 replications (20). A cost-effectiveness (CE) plane was used to graphically 
present the uncertainty around the cost-effectiveness ratio. 
Sensitivity analyses were performed on lower genotyping costs (-33%; €100 instead 
of €150), as these costs differ between laboratories and are expected to decrease 
in the coming years. Analyses without cost of biologicals or productivity losses 





This analysis included all patients of the TOPIC trial (excluding those with missing 
data on all costs or on quality of life measurements) resulting in 381 patients in 
the intervention group, and 347 in the control group. There were no statistically 
significant baseline differences between the two groups, except for the percentage 
of patients treated with biologicals (Table 1, intervention group, 3.7%; control 
group, 7.2%; p = 0.035). This is in line with the total patient population (n=783) of 
the TOPIC trial, as reported previously (7). 





Male, n (%) 173 (45.4) 156 (45.0)
Age, y (SD) 42.4 (15.8)a 41.1 (15.9)b
Age of disease onset, y (SD) 37.0 (15.5)a 35.6 (14.9)c
Disease duration until treatment start, median 
(minimum-maximum), y











Drug dose start, median (minimum-maximum), mg/kg
  Azathioprine
  6-mercaptopurine





















TPMT variant, n (%) 40 (10.5) 34 (9.8)







Utility start, mean (SD)





TPMT, thiopurine S-methyltransferase. The table shows means (SD), medians (min-max) or n (%) for the 
different characteristics. There were no statistically significant baseline differences between the two 
groups (p ˂ 0.05), except for biological use (p = 0.035).
an=381. bn=346. cn=347. dn=247. en=229. fn=134. gn=118. hn=160. in=149. jn=98. kn=97. ln=375. mn=335. 
nn=266. on=243.
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Costs
The mean costs for (clinical) consultations with, for example, a gastroenterologist or 
surgeon, diagnostic procedures and hospital admissions, medication use, and indirect 
costs in the form of productivity losses for each group during the 20-week assessment 
are shown in Table 2. The outcomes did not show statistically significant differences 
between the groups, except for medication use between the populations when missing 
data are excluded (intervention group = €302; control group = €387; P = 0.047). 
Table 2  Costs of consultations, diagnostic procedures and hospital admissions, medication use, and 
indirect costs for both treatment strategies
Type of costs Intervention Control
Total populationa Population with 
complete data
Total populationb Population with 
complete data
Consultations €0 (0-1,576) €114 (33-1,576)c €0 (0-1,836) €115 (33-1,836)d
Diagnostic procedures 
and hospital admissions
€31 (0-20,671) €269 (12-20,671)e €41 (0-11,900) €198 (12-11,900)f
Medication use €302 (0-14,180) €302 (1-14,180)g €386 (5-15,034) €387 (5-15,034)h
Indirect costs €0 (0-27,800) €1,633 (70-27,800)i €0 (0-27,800) €1,355 (104-27,800)j
Costs are presented as medians with minimum and maximum values. There were no statistically 
significant differences between the groups (p ˂ 0.05), except for medication use (p = 0.047).
an=381. bn=347. cn=118. dn=205. en=380. fn=95. gn=96. hn=187. in=345. jn=92.
Cost-effectiveness 
The incremental costs and effects on QALYs across both groups resulting from the 
1000 bootstrapped replications are presented in Table 3 and Figure 1. The mean 
incremental costs were -€52 for the intervention, but with wide variability (95% 
percentiles: -682, 569); the mean incremental QALYs were 0.001 (95% percentiles: 
-0.009, 0.010). The simulated ICERs were scattered over all four quadrants of the CE- 
plane. In 57% of the replications, the intervention resulted in QALYs gained through 
the intervention (north-east and south-east quadrant in Figure 1), of which 32% of 
the replications also resulted in lower costs also (‘dominant’, south east quadrant). In 
19% of the replications, the intervention resulted in reduced QALYs and extra costs 
(‘inferior’, north-west quadrant). In the other 24% of the replications, the intervention 
induced QALY losses in combination with lower costs (south-west quadrant). 








Intervention €2,181 (€1,822, €2,546) -€52 (-€682, €569) 0.302 (0.295, 0.308) 0.001 (-0.009, 0.010)
Control €2,232 (€1,789, €2,741) 0.301 (0.294, 0.308)
Costs and QALYs are presented as means with 95% percentiles resulting from non-parametric bootstrap 
with 1000 replications. QALYs, quality adjusted life years.
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Figure 1. Cost-effectiveness (CE) plane. The CE plane shows the results of the non-parametric bootstrapping with 
1000 replications representing the uncertainty surrounding the cost-effectiveness ratio of the initial CE analysis. 
The percentages indicate the amount of the bootstrapped replications (n=1000) in the corresponding quadrant. 
Sensitivity analysis with lower genotyping costs of €100 (-33%) showed there was 
still no statistically significant difference (95% percentiles: -€732, €519) between 
the intervention and control groups (Table 4). This can also be seen in the CE-
plane, which showed slightly more replications in the southern quadrants (63% 
vs 56% in the base case analysis) (Figure 2A). Exclusion of the productivity losses 
also resulted in no statistically significant difference (95% percentiles: -€115, €456) 
between the two groups (Table 4). This was also reflected in the CE-plane, where 
85% of the replications were in the northern quadrants (Figure 2B). In 37% of 
these replications, there were also fewer effects (‘inferior’, north-west quadrant). 
The relatively strong effects of productivity loss were mainly due to a few patients 
(one in the genotyping group, three in the control group) being on sick leave for 
the whole length of the study. Excluding these patients from the analysis showed 
almost the same increase in costs as excluding the entire productivity costs from 
the analysis (see Supplementary Figure 1, Supplementary Table 2). 
As biological use at baseline was significantly different between the two strategies, 
the influence of costs for biologicals on our results was also evaluated. Sensitivity 
analysis leaving out these costs showed that there was no significant difference 
(95% percentiles: -€531, €632) (Table 4).
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Table 4 Costs and effects of the sensitivity analysis of both treatment groups based on non-parametric 
bootstrap with 1000 replications
Lower genotyping costs of €100 (-33%)
Treatment 
strategy
Costs Incremental costs QALY Incremental QALYs
Intervention €2,133 (€1,748; €2,565) -€97(-€732; €519) 0.302 (0.295; 0.308) 0.001 (-0.008; 0.010)




Costs Incremental costs QALY Incremental QALYs
Intervention €1,187 (€985; €1,417) €161 (-€115; €456) 0.302 (0.295; 0.308) 0.001 (-0.009; 0.010)




Costs Incremental costs QALY Incremental QALYs
Intervention €1,994 (€1,633; €2,348) €75(-€531; €632) 0.302 (0.295; 0.308) 0.001 (-0.009; 0.010)
Control €1,919 (€1,496; €2,356) 0.301 (0.294; 0.308)
†Costs and QALYs are presented as means with 95% percentiles resulting from non-parametric bootstrap 





Figure 2 (A). Results of the non-parametric bootstrap, when genotyping costs were lowered with 33%. (B). Results 
of the non-parametric bootstrap, when productivity losses were not taken into account. The percentages indicate 
the amount of the bootstrapped replications (n=1000) in the corresponding quadrant.
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Discussion
The TOPIC trial showed that there was no overall difference in a haematological 
ADRs between the intervention and control groups , although this secondary 
analysis showed that pre-treatment TPMT genotyping to determine individualized 
dosing of thiopurine treatment in IBD patients is still a cost-neutral intervention. In 
our study, the mean costs in the intervention group were not statistically significant 
(95% percentiles: -€682, €569). Sensitivity analysis showed that lowering of the costs 
for TPMT genotyping, excluding biological costs or lack of accounting for productivity 
losses did not substantially alter these results. Although productivity costs greatly 
influenced the final results, this seems a coincidence as baseline characteristics 
between the two groups were the same. Importantly, we saw no difference in QALYs 
between the strategies, with a mean difference of 0.001 QALYs (95% percentiles: 
-0.009, 0.010).
Based on several earlier reports (8-12) we expected to find a difference in costs 
(medical and societal) and QALYs between the two intervention groups (7, 8, 21). 
However, this could not be confirmed with our available data, as there were no 
differences in the proportions of patients with a haematological ADR between the 
intervention and control group and due to the low prevalences of both the TPMT 
variants (±10%). If effect sizes achieved with the intervention do not reach very high 
values, analyses at the population level will be too insensitive to pick these up (22, 
23), especially in a background where disease and the treatment with thiopurines 
already have considerable impact on the costs (especially productivity losses) 
and the quality of life in the majority of patients (24, 25). In addition, due to the 
small number of patients with a genetic variant, we did not observe a difference 
in costs and QALYs in patients with or without a variant of TPMT (data not shown). 
Furthermore, it has been suggested that TPMT testing is mainly relevant for patients 
with no TPMT activity, as these could develop major adverse events. However, the 
prevalence of these variants is very low (0.1% in the TOPIC trial). Although on an 
individual level these will cause lower quality of life and an increase in costs, they will 
probably cause no significant differences on a population level. Finally, the disease 
and treatment with thiopurines already have a large impact on the costs (especially 
productivity losses) and quality of life in the majority of patients (24, 25). 
Our study was in line with the results of the only other prospective cost-
effectiveness analysis, the TARGET-study (8, 9). These authors concluded that there 
was a probability of 71% that pre-treatment genotyping, at approximately the 
same price for screening (£150), would be a cost-effective strategy at a willingness 
to pay (WTP) of £20,000 per QALY. In our study from a societal perspective, a 
slightly smaller probability of 56% was found at approximately the same WTP 
(€20,000). Our study was also in line with other cost-effectiveness studies that 
have made use of cost-effectiveness modelling (10-12). Therefore, although not 
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significant in the case of the two prospective studies, all cost-effectiveness studies 
so far suggest that TPMT testing prior to thiopurine treatment in IBD patients could 
be beneficial, or at least cost-neutral, from an economic perspective. 
Our study should be viewed in the context of some strengths and limitations. 
Clear strengths of the TOPIC study are its prospective randomized design, size 
of the study, and use of validated outcome measures. Another strength is that 
gastroenterologists made the final decision to start, change dosage, or stop 
thiopurine treatment, and even the advised treatment adjustment based on 
a patient’s genetic profile was not followed in all cases (7). The study therefore 
provided a realistic reflection of the clinical treatment procedures in IBD patients.
 
Our study also had some limitations. The first limitation concerned the relatively 
short follow-up time of 5 months. Potential long–term costs and effects related 
to pre-treatment TPMT genotyping were therefore not estimated. However, the 
majority of thiopurine treatment-related haematological ADRs occurs within 
4 months of treatment initiation, we are likely to have captured the majority 
of genotype-related cost differences (7, 8, 26). A second limitation could be the 
testing of only three common TPMT variants. Therefore we could have missed 
deficient cases at risk of developing leukopenia. In the TOPIC trial 12 patients 
without one of the three pre-tested variants had low TPMT enzyme activity 
(<60 mg 6-methylguanine/mmol haemogloblin/h), and one of these patients 
developed leukopenia (7). This confirms that genetic testing cannot explain all 
cases of decreased enzyme activity, but this is not necessarily harmful. In addition, 
complete sequencing of the coding region of the TPMT gene revealed a known 
silent variant in four of the patients (TPMT*1S), indicating that we did not miss 
any relevant genetic variant . An alternative for genetic testing could be enzyme 
testing. In the TOPIC trial we showed that patients carrying a genetic variant had 
a lower TPMT enzyme activity than patients without a variant. This confirmed that 
enzyme based testing and genetic testing can give comparable results. In addition, 
the costs of genetic testing and enzyme-based testing are comparable . However, 
genetic testing is a well-accepted alternative to enzyme-based testing (27).
A third potential limitation was that the study might have been partly unblinded; 
the gastroenterologist might have identified patients with a genetic variant in 
the intervention group based on the (lower) dose advice for other patients in the 
intervention and control groups who all received standard dose advice. This might 
have resulted in an overestimation of costs in the TPMT-variant group, masking any 
cost savings, if gastroenterologists had treated the intervention group differently 
from the control group resulting in more use of healthcare resources in these 
patients. Missing EQ5D-3L data at one of the two time points (week 0 and/or week 
20) had to be imputed, which also represents a potential limitation of the study. 
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However, we saw no difference in the number of missing data or the reason for 
missing data (e.g. patients did not complete the questionnaire, or pages from the 
returned questionnaire were missing) between the two groups (data not shown). 
Imputation is therefore unlikely to have influenced the observed difference in 
QALYs. Lastly, the difference in biological use at baseline between the two groups 
was a limitation. As shown in the outcomes of the different cost components, 
medication use was also significantly different between the intervention and 
control groups after 20 weeks. Including these costs, although not related to the 
intervention of interest, probably resulted in an underestimation of the difference 
between the intervention and control groups. Sensitivity analysis excluding costs 
for biologicals still indicated that the intervention was cost-neutral without a 
change in incremental QALYs compared to no genotyping. We decided not to 
perform further post-hoc analysis by excluding these patients, because this could 
have led to baseline imbalance and a lower statistical power.
Recent data have suggested that nudix hydrolase (NUDT) mutations may be equally 
important as TPMT mutations in predicting thiopurine-induced myelotoxicity, 
even in European populations (28). Pre-treatment genotyping for NUDT, with or 
without TPMT, to optimize thiopurine treatment could therefore be an interesting 
area for future research regarding the effects on preventing haematological ADRs.
 
Despite the existence of guidelines concerning thiopurine dosing based on TPMT 
activity and cautions printed on thiopurine drug-labels, the uptake of genetic TPMT 
testing prior to thiopurine treatment has been relatively limited. TPMT testing 
cannot replace haematological monitoring, as leukopenia is not fully predictable 
by TPMT activity (29). We believe that TPMT testing can be viewed as a good option 
to optimize dosing at the start of treatment especially for those patients carrying a 
genetic variant in TPMT. Studies have shown that the rate of leukopenia decreases 
despite intensive haematological monitoring (7, 8). 
In conclusion, our study shows that thiopurine dosing based on TPMT genotype 
provides a cost-neutral opportunity to individualize of thiopurine treatment in IBD 
patients, as it prevents haematological ADRs in patients at risk without extra costs 
to the healthcare system. 
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Supplementary files
Supplementary table 1 Unit costs of resource use, updated to 2016 Euros 
Cost price Reference










Emergency room 259 14
Gynaecologist 113 14
General practitioner 33 14
Medication use Cost price per DDD (€)
Mesalazine 0.88 16
Mesalazine (enema) 0.05 16
Mesalazine (suppository) 2.25 16
 Olsalazine 1.33 16
Sulfasalazine 0.41 16
Sulfasalazine (suppository) 16.96 16
Beclometasone (enema) 3.57 16





Prednisolone (injection 1.14 16
Prednisolone suppository 0.95 16
Dexamethasone 0.15 16










Ciclosporin (injection) 7.25 16
Infliximab 21.70 16
Adalimumab 39.44 16
Diagnostic and surgery procedures Cost price per type of procedure (€)
Thorax X-ray 41.12 15
Thorax CT 172.29 15
Therapeutic Drug Monitoring 11.95 15
TPMT genotyping 150.00 15
Laboratory 14.22 15
Mantoux test 16.38 15
Colonoscopy 375.16 15
Rectosigmoidoscopy 183.47 15
MRI scan 297.95 15
CT scan 167.63 15
Abdominal ultrasonography 85.28 15
Abdominal X-ray 43.62 15
Endoscopy 375.16 15
Esophagogastroduodenoscopy 473.24 15
DEXA scan 11.05 15
Exploratory Laparotomy 8,421.69 15
Resection 15,161.78 15
Plastic surgery 5,176.58 15
Productivity losses Cost price per working hour (€)
34.75 14
*No price per DDD known, unit price
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Supplementary table 2  Costs and effects of both treatment strategies based upon non-parametric 







Genotyping €2,115 (€1,754; €2,460) €122 (-€419; €624) 0.302 (0.295; 0.308) 0.001 (-0.008; 0.010)
Control €1,993 (€1,636; €2,408) 0.301 (0.293; 0.308)
†Costs and QALYs are presented as means with 95 percentiles resulting from non-parametric bootstrap 
with 1000 replications. QALYs, quality adjusted life years 
Supplementary figure 1. Results of the non-parametric bootstrap, when outliers in the productivity losses were 
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New knowledge and innovations are rapidly evolving in health care, causing 
considerable pressure on health care systems’ budgets (1). Decision makers face 
the challenge of making wise decisions regarding the implementation of these 
technologies while controlling health care expenditures (2). In recent years, we 
have witnessed a rapid development in biomarkers, which hold the potential of 
more personalized health care. This raises the question whether the introduction 
of biomarkers in health care will further contribute to a rise in health care costs, 
or whether they could be used to make more efficient use of available treatment 
options. To address this issue, we need to understand how the use of biomarkers 
may alter the health care trajectories of patients and how this affects patients’ 
outcomes and the associated resource utilization. Whether this renders health 
care more affordable not only depends on the biomarkers themselves, but also on 
the context in which they are being used. 
Cost-Effectiveness of Biomarkers
A first step in such an inquiry is to explore the extra costs that are associated with 
the use of a biomarker, the impact on patients’ health, and any extra downstream 
costs or savings (3). Use of a biomarker can affect treatment decisions, altering 
a patient’s health prospects and use of health care resources. In theory, a 
more personalized approach could improve quality of life and save health care 
resources for instance by preventing adverse drug reactions (ADRs) or avoiding 
futile treatment. In such cases, the benefits for some patients could outweigh the 
extra costs of screening all patients. This is expressed in a cost-effectiveness ratio 
(ICER), representing the extra money that needs to be spent in order to gain one 
extra unit of effect, for instance a quality-adjusted life year (QALY), when compared 
with an alternative strategy. To distinguish between what is cost-effective or not, 
a willingness to pay threshold (WTP) is used, representing the maximum amount 
of money that is considered acceptable to gain one extra unit of effect. If the 
cost-effectiveness ratio is below this WTP, the intervention is considered cost-
effective. Cost-effectiveness analyses can be performed alongside a clinical trial or 
conducted using a modelling approach (4). 
A lot of research has been conducted to estimate the added value of using various 
biomarkers compared with current practice. Examples are from cardiac surgery (5), 
coronary artery bypass graft surgery (6), Alzheimer disease (7), non-small-cell lung 
cancer (NSCLC) (8, 9), breast and ovarian cancer (10), cystic fibrosis (11), colorectal 
screening (12) and viral infections (13). These studies looked at the added value of 
biomarkers by better diagnosing diseases, prioritizing patients for a specific health 
intervention, or preventing adverse events. Most of these studies concluded that 
the use of biomarkers was a cost-effectiveness approach compared with current 
practice, given a specific WTP threshold (5, 6, 10, 11, 13). However, in some cases 
this conclusion was strongly dependent on a number of model parameters, such as 
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prevalence of the disease. Examples where biomarkers were not found to be cost-
effective were related to NSCLC. In these cases, the low biomarker frequency in the 
target population appeared to be the main reason for this (8, 9). However, publication 
bias might lead to an overly optimistic view of the cost-effectiveness of biomarkers. 
This concern has been raised for biomarkers in the field of cardiovascular disease, 
dementia, peripheral depression, and cost-effectiveness studies in general (14-18). 
However, these studies also show what factors may be important in determining the 
cost-effectiveness of biomarkers. In the following, two case studies are presented 
from the field of pharmacogenetics to explore this issue further. 
Key Parameters in Cost-Effectiveness Analysis of Pharmacogenetics 
A number of parameters have been reported to be of critical importance on the 
cost-effectiveness pharmacogenetics (19-22). In this paragraph we will highlight 
these parameters and describe the basic principles how these could affect the 
cost-effectiveness of pharmacogenetics:
• Prevalence of the genetic mutation
A higher prevalence of a specific genetic mutation in the general or patient 
population, the more impact pharmacogenetic testing could have. If more 
patients have the mutation, the more patients could potentially benefit 
from the intervention associated with pharmacogenetic testing. 
• Prevalence of ADRs
If an ADR occurs frequently due to treatment with a certain drug, 
more effect can potentially be gained when optimizing treatment with 
pharmacogenetic testing. If, however, an ADR is very rare, the potential 
impact of pharmacogenetic testing is low. Only a few patients would then 
benefit from it, whereas other patients are screened unnecessarily for a 
genetic variant. 
• Severity of the ADRs
The more severe an ADR is that can be prevented with an intervention after 
genotyping, the more impact it can have on the outcomes of genotyping. For 
instance, by preventing ADRs the quality of life of patients could increase 
and could also have an influence on the overall health care cost, because 
costs related to the ADR (i.e. hospital admissions, diagnostic test) and loss 
of quality of life are prevented. 
• Genotype – phenotype association (penetrance)
If the relationship between genotype and phenotype is weak, testing and 
adjusting treatment accordingly have little consequences for a patient, 
because their genetic profile does not results in an expected phenotype. 
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Therefore treatment adjustments were unnecessary and could even result 
in losses in quality of life or treatment effect due to under treatment. 
• Test accuracy of the genetic test
The test accuracy can be expressed as sensitivity, specificity, positive 
predictive value and negative predictive value. The positive predictive 
value is the proportion of patients with a genetic variant that do indeed 
get for instance an ADR while treated without adjustments. The higher 
this proportion, the more patients will benefit for the genetic test and 
the resulting treatment adjustments. The sensitivity is the proportion of 
patients with an ADR and a genetic variant out of all patients with an ADR. If 
this proportion is high it means that only a few patients do get an ADR while 
they do not have the genetic variant; in other words you will find many of 
those patients who could benefit the most. If the false negative rate is high, 
this will result in “under treatment” because patients still experience side 
effects. If the test finds patients that do not need treatment adjustments 
(false positives), then this could lead to ”overtreatment” also resulting in 
less treatment effect of the pharmacogenetic test.
• Costs of genetic test
The higher the costs for screening patients, the more costs have to be earned 
back by preventing ADRs or increasing treatment effect. These same occurs 
vice versa; how cheaper screening would become the easier these costs are 
compensated by preventing ADRs or increasing treatment effect.
• The effect and costs of the alternative treatment
Testing positive on a genetic test will induce an alternative treatment, dose 
adjustment or another treatment, for those patients with a genetic variant. 
The higher the costs directly related to this alternative treatment or due 
to its length, the more money has to be ”earned back” by preventing ADRs 
or gaining more treatment effect. Furthermore, the alternative treatment 
should really be a better option in terms of effectiveness and toxicity 
otherwise you will gain not enough to outweigh the extra costs of the 
genetic test. 
Illustrative Cases to See the Influence of Key Parameters on the Cost-
Effectiveness 
The impact of different key parameters described above on the cost-effectiveness 
of pharmacogenetics will be illustrated by two examples of pharmacogenetic 
testing; namely 1) factor V Leiden in combination with oral contraceptives, and 2) 
HLA-B*5701 and antiretroviral therapy of abacavir. 
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1. Factor V Leiden in combination with oral contraceptives
Factor V Leiden (fVL) mutation leads to a higher chance of venous 
thromboembolism (VTE), including deep vein thrombosis (DVT) and 
pulmonary embolism (PE). Another risk factor for VTE is the use of oral 
contraceptives (OC). Knowledge on the fVL gene activity requires genotyping 
for this variant allele of all potential OC users. The question arises if the 
costs of screening outweigh the benefits of preventing VTE, which can be 
achieved by treatment optimization. 
An earlier cost-effectiveness study by Creinin et al. at testing for fVL 
before prescribing oral contraceptives concluded that it was not a cost-
effectiveness strategy, mainly because of the prevalence of fVL and VTE, 
and the price of screening (23). Their estimated risk of a VTE in women with 
fVL using OC was 140 in 100,000. With a prevalence of fVL of almost 5% the 
ICER was estimated to be $4.8 million per year of life saved when screening 
all 20 year-old women. When the prevalence would rise to 99%, this ratio 
would become $404,000 per year of life saved. This shows that even with 
unrealistic prevalence estimates, testing every 20 year-old women remains 
not cost-effective. When the price of screening would be discounted to 
34.5% of the current prices, the ICER would still be $1.7 million per life 
year saved. Screening for fVL can only become cost-effective when genetic 
testing is almost free of charge. 
This study illustrates that in the general population screening for fVL in 
order to prevent a first event of VTE is not a very interesting strategy, in 
terms of cost-effectiveness (23). The reason for this is the low prevalence 
estimates of fVL and VTE. The prevalence of these genotypes is low being 0%-
1% for homozygous fVL variant alleles, and about 3% being heterozygous 
for a fVL variant allele in the white population. The baseline risk of VTE is 
in the general population approximately 1: 10,000, so for patients with fVL 
and using OC this is still just 35: 10,000. Due to these low prevalences too 
much patients are screened unnecessary to save a life year by preventing 
VTE. Even at unrealistic genetic test prices or prevalence rates this strategy 
would not become cost-effective. However, in high risk groups, like patients 
with a history of VTE, screening might become more interesting, due to 
higher prevalences of fVL and VTE. 
2. HLA-B*5701 and antiretroviral therapy of abacavir
Abacavir is an antiretroviral therapy often used in the treatment of HIV. 
One of the adverse reactions of abacavir is a hypersensitivity reaction 
(HSR) occurring within 6 weeks of treatment, and which in some cases can 
even be lethal. Different studies showed however that these reactions are 
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strongly associated with the HLA-B*5701 allele, which is present in about 
5%-8% of the white population. About 50% of the patients that have this 
allele develop hypersensitive reactions. These ADRs can be prevented by 
given several other treatment options instead of abacavir. 
A cost-effectiveness analysis by Hughes et al. concluded that pre-treatment 
screening for HLA-B*5701 can be cost-effective depending on the willingness 
to pay for avoiding a HSR (24). However, the level of cost-effectiveness 
strongly depended on the treatment costs after genotyping, in other 
words the alternative treatment patients received instead of abacavir. The 
cheaper the alternative, the less money have to be spent to avoid a HSR 
compared with no screening ranging from ICERs of “dominant” (lower costs 
and more effect gained with testing) for the cheapest alternative up to 
€31,725 per HSR avoided for the most expensive alternative. Furthermore, 
test sensitivity and costs associated with HSRs were important parameters. 
When test sensitivity was higher (80%) compared with the base-case the 
ICER dropped to €3,447 per HSR avoided compared with no testing, and 
when costs associated with HSRs was higher (€5,000) the ICER dropped to 
€4,663. Vice versa, when test sensitivity (40%) and costs associated with 
HSRs (€500) were lower, ICERs increased respectively up to €10,799 and 
€9,938 per HSR avoided compared with no testing. As the prevalences of 
the HLA-B*5701 allele are relatively high (5% - 8%), the positive predictive 
value of the test is high (at least 50% of the patients with a positive test 
develops a HSR), the costs associated with HSRs could be high (€11,587 
(24); €28,000 (25)), and the consequences of these reactions could even be 
lethal, screening for this allele pre-emptive in the treatment with abacavir 
is already obligatory.
Affordability of Biomarkers
Although most biomarkers could be cost-effective, they need not necessarily 
make health care more affordable. This follows from the fact that interventions 
can be cost-effective, but still have a considerable budget impact (26, 27). In 
order to become more affordable it is necessary that when implementing a new 
innovation like biomarkers, existing health care intervention(s) are disinvested. 
This disinvestment should then liberate sufficient resources to fund the new 
innovation, while not resulting in less health benefits (26). So in case of biomarkers 
to let health care become more affordable, it should first be cost-effective 
to show the added value compared with standard care. Subsequently, when 
implementation is considered we must be willing to disinvest current health care 
programs in order to control health care expenditures (28). 
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Early HTA and Biomarkers
Could we already have predicted in case of fVL that it would not be an cost-
effective and affordable approach, although evidence was not completely 
available? By getting an idea if new strategies concerning personalized medicine 
are potentially cost-effective, we could target the strategies that are most 
promising instead of researching and developing a biomarker for every disease or 
drug. Because personalized medicine, including pharmacogenetics, is a relatively 
new approach in health care, many of the implications are not clear. For example, 
for pharmacogenetics there is a relatively low amount of scientific evidence 
concerning the effectiveness of pre-emptive screening (29).
Early HTA could offer a solution by saying something about the potential impact of 
a new innovation or strategy already at the beginning of the development process, 
so even before considering implementation (where most cost-effectiveness 
analysis are performed). If the potential impact is small, pharmacogenetics is 
probably not a very interesting strategy to develop as this will not improve current 
practice that much, and vice versa. Early HTA also gives an indication about how 
well the current care is performing, and if there is any room for improvement at 
all (“effectiveness gap”). Knowing information about the potential impact could 
support the development of pharmacogenetics (which gene-drug interactions 
could be interesting to implement?) and also price ceiling (at which price a 
pharmacogenetic test could be potentially cost-effective?). This could eventually 
justify the costs of clinical trials and other related research activities in the field 
of pharmacogenetics. If there is no room for improvement by pharmacogenetics, 
research activities should preferably be terminated. 
In order to show the idea of early HTA, we evaluate the case of HLA-B*5701 and 
abacavir again with the evidence that was available at the time pharmacogenetic 
testing was considered. 
In the HLA*B5701 case we saw that in about 8% of the patients the genotype was 
present. Therefore, if all these patients would develop a hypersensitivity reaction, in 
a cohort of 100 patients you could prevent normally eight cases of hypersensitivity. 
The median costs associated with mild HSRs were estimated at €2,611, ranging from 
€500 to €11,857. For fatal reactions costs of €28,000  are mentioned. So preventing 
eight cases would result in case of mild hypersensitivity in savings of about €21,000, 
ranging from €4,000 to €95,000. In case of fatal reactions this could even result in 
savings of €224,000, when all cases are prevented. So a pharmacogenetic test with 
100% sensitivity and specificity could costs around €210 (ranging from €40 to €950 
when we take the median costs of a mild HSR into account, and even more when all 
the reactions have a fatal outcome. This seems a very realistic price as the average 
costs of most pharmacogenetic test lies around the €150. 
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Subsequently we know that the sensitivity of the HLA*B5701 screening is about 
50%. This means that with screening, of the eight patients potentially developing a 
HSR by using abacavir in a cohort of 100 patients, half of them could be prevented 
by a genetic test and change in medication. The specificity of the test is almost 
100%, which means that in patients with a HSR, a variant is not present. When 
we again take into account the median costs of a mild HSR, €10,444 (ranging 
from €2,000 to €47,428 are the maximum additional costs at which HLA*B5701 
screening will be cost-effective compared with current practice. The price of the 
pharmacogenetic test should therefore not be more €104 (ranging from €20 to 
€474 to be cost-effective. However, as we know that the costs of the HSR are much 
higher with increasing severity or fatal ending, the price of the test can even be 
much higher. So the average price of €150 per pharmacogenetic test is probably 
very easily earned back in the case of HLA-B*5701 and abacavir. 
These examples shows that with little evidence about the important key parameter, 
such as prevalences of the allele and ADRs, the specificity and sensitivity of the 
genetic test, the cost associated with the test and ADRs, this could already tell you 
something about the potential impact of pharmacogenetic testing. It is important 
to mention that at the time more evidence is gathered, cost-effectiveness analysis 
should be performed in order to say something about the “real” impact. 
Future directions 
The lessons learned from the examples of pharmacogenetics can be translated 
to various kinds of biomarkers and personalized medicine. Imagine that a new 
biomarker is discovered that is a predictor for a certain health state. The question 
then is, is this biomarker (and related interventions) interesting to implement 
in current practice because it makes health care more affordable? These kinds 
of evaluations could already be done at a very early stage of the Research and 
development (R&D) process of specific biomarkers, by using methods related to 
early HTA. These evaluations give a first indication about the potential impact 
of a new biomarker. For example, the biomarker is probably not becoming a 
cost-effective approach when evidence surrounding the key parameters is very 
unfavorable, such as very low prevalences of the biomarker or the disease/ADR it 
could potentially prevents. This was also the case in the cost-effectiveness studies 
concerning Alzheimer disease, NSCLC and venous thrombo-embolism, resulting in 
not or uncertain cost-effective strategies (7-9, 23). Knowing this information about 
unfavorable evidence should already mean that these specific biomarkers are not 
interesting to further investigate, develop and implement in this context. However, 
for potential interesting biomarkers you can predict the effectiveness gap that is 
left behind by current treatments. Depending on the effectiveness gap, productivity 
costs/future research costs can be compensated by gaining more effect and 
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therefore reducing costs compared with current practice. This evaluation shows 
if it worthwhile spent more time and money in this specific biomarker or that 
R&D should focus on other areas of biomarkers. For example in areas like BRCA 
screening in women with ovarian cancer (10) or screening for the HLA*B5701 gene 
(24) instead of NSCLC (8, 9) or screening for fVL (23). After the decision to develop 
the intervention, the next step is to gather evidence surrounding at least the 
most important parameters that determine the cost-effectiveness. This evidence 
is used to estimate if the new intervention is really going to be cost-effective 
compared with current practice. In case of missing evidence, threshold analysis 
could provide information how effective the biomarker should be to become 
cost-effective. Finally, a decision should be made if the biomarker is interesting 
enough to implement in current practice, such as in case of the biomarkers for 
cardiac surgery or cystic fibrosis. Therefore, we must decide if we are willing to 
pay this amount of money to gain health benefits, and which current health care 
interventions are disinvested to control health expenditures. 
It is important to mention that all these evaluations are only useful when we are 
willing to make choices about terminating R&D processes of certain biomarkers. 
This, however, raises the question whether it is possible to stop or steer all new 
innovations. Some innovation processes are started years ago, for example in 
drug development. Consequently, companies are maybe not able to terminate 
their R&D processes as a lot of money was already invested. In addition, over time 
new discoveries concerning the innovation, like new target populations, could 
make an innovation from unfavourable to favorable in economic terms. All these 
considerations need to be kept in mind when performing and interpreting results 
of early HTA evaluations. Therefore these evaluations should preferably start at 
the beginning of the R&D process and be part of the decision-making process. 
This will help to allocate resources to more attractive projects, for example when 
pharmaceutical companies are deciding about which drugs to develop further and 
which to terminate timely (30-32). In addition, termination of projects is probably 
easier when doing these evaluations from the beginning of the R&D process, as 
investments are low at that stage. This should lead to researching and developing 
only the most interesting biomarkers, and eventually resulting in a (more) 
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6CHAPTER 6Perceived barriers and solutions to the use of pharmacogenetics in clinical practice: A mixed methods study
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Background. The field of pharmacogenetics (PGx) tries to improve drug 
treatment by using genetic information to prevent side effects and enhance drug 
effectiveness in individual patients or patient subgroups. In spite of its promises, 
however, clinical practice appears hesitant in adopting the technology. This study 
explores the attitudes towards, knowledge of, experiences with, and views on PGx 
among various stakeholders to identify potential barriers to and facilitators of its 
use in clinical practice.
Methods. We used mixed methods to collect detailed information on stakeholder 
perspectives on the relevance and clinical implementation of PGx. All pharmacist 
members of the Royal Dutch Pharmacists Association (KNMP) were invited to 
complete a questionnaire and various other relevant stakeholders to participate 
in an interview inquiring about their views on PGx and the potential obstacles 
and solutions to its implementation. We subsequently conducted a qualitative 
thematic analysis to identify major themes. 
Results. The greater majority of the respondents (questionnaire: n=382; interviews: 
n=9) had a positive attitude towards PGx, holding that the technique could have an 
important role in optimising drug treatment in clinical practice. A majority indicated, 
however, that, to date, there is a lack of robust evidence regarding its clinical utility, 
added value, and cost-effectiveness, hampering the uptake of PGx testing and 
clinically useful guidelines and thus the implementation of PGx in daily practice. Other 
potential barriers for successful implementation the participants mentioned included 
knowledge gaps among health-care providers and patients, unclear policies regarding 
the reimbursement of costs related to PGx, and the absence of well-defined modes of 
collaboration between pharmacists and general practitioners.
Conclusions. Our study showed that PGx was generally deemed a promising 
approach to personalized drug treatment with a potential for broad implementation 
provided that its benefits are supported by relevant and robust scientific evidence 
to come to uptake of PGx testing in clinically useful guidelines. Uptake of PGx 
testing in guidelines will also contribute  to overcome other potential barriers that 
are perceived by stakeholders.
Keywords: pharmacogenetics, mixed methods study, barriers and facilitators, 
implementation, clinical utility, added value, cost-effectiveness
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Introduction
In the last few decades there has been growing interest in personalized medicine 
as it is recognized that uniform treatments do not fit all patients (1). One example 
of personalized medicine is pharmacogenetics (PGx), where genetic profiles are 
identified to explain variability in individual drug responses, both in terms of 
clinical effects and adverse events (1, 2). 
PGx is typically based on associations between a certain genotype, mostly defined 
by a single nucleotide polymorphism (SNP), and adverse drug reactions (ADRs) 
or lack of effectiveness, with the known association(s) being used to personalize 
treatment recommendations based on the patient’s genetic variation. The United 
States Food and Drug Administration  (FDA) and the European Medicines 
Agency (EMA) have currently approved the labelling of at least 200 drugs to include 
information about how to adapt treatment based on genetic profiles (3, 4) on the 
assumption that adjusting and thereby optimizing drug treatments will prevent 
ADRs and/or lead to improved drug effectiveness (5-8). 
In their capacity as medication experts, pharmacists play an important role in 
applying PGx information to relevant prescription drugs. They combine PGx data 
with their extensive knowledge of pharmacology to provide informed personalized 
treatments and improve drug safety (9, 10). Although they and most other potential 
users of these recommendations have a positive attitude towards its concepts, 
the uptake of PGx testing in clinical practice is slow and limited (1, 11-13). The 
total number of genetic tests carried out in clinical practice is still moderate, while 
the tests that are performed mostly focus on a small number of genes (14). This 
prompts the question what barriers prevent or which facilitators promote the use 
of PGx in clinical practice. Answers to this question may help researchers, policy 
makers, professional associations, health-care professionals, and other relevant 
stakeholders to formulate their research questions and policy agendas regarding 
PGx implementation.
To this end, we explored the attitudes, knowledge, and experiences among 
relevant stakeholders to identify factors that are thought to impede and those 





A mixed methods design was used to explore the attitudes, knowledge, and 
experiences regarding PGx to ultimately identify potential facilitators of and barriers 
to its implementation. Quantitative data were collected using a questionnaire and 
combined with qualitative data derived from semi-structured interviews. 
Sampling and recruitment
Questionnaire. All the pharmacist-members of the Royal Dutch Pharmacists 
Association (KNMP) (n=3,461) were sent an invitation by e-mail with a link to a 
dedicated online Dutch-language questionnaire. We chose this stakeholder group 
because The American Society of Health-Systems Pharmacists (ASHP) and American 
Pharmacists Association (APhA) had concluded that pharmacists are in the lead 
when it comes to the implementation of PGx (9, 10). The members of the KNMP 
include community pharmacists, hospital pharmacists, and outpatient pharmacists. 
After 2 weeks a reminder was sent in case of no reply. We used the online survey 
tool Questback (Oslo, Norway) for our questionnaire. Participants were asked to 
complete the questionnaire between 14 September 2016 and 3 October 2016. 
Participation was voluntary and all responses were handled anonymously. 
Semi-structured interviews. We additionally selected a broad range of relevant 
stakeholders for our semi-structured interview, defining stakeholders as actors 
who are directly involved in the drug decision-making process and those that are, 
or might be, affected by any action taken to personalize drug treatment based 
on PGx recommendations (15-17), having a formal (e.g. pharmacists, general 
practitioners (GPs), or medical specialists), organizational and financial (health 
insurance companies), or policy-making (decision-makers) interest. We accordingly 
contacted medical specialists, pharmacists, geneticists, patients, GPs, health-care 
insurance employees, policy makers from our National Healthcare Institute, and 
policy advisors of the KNMP. Because in the Netherlands gastroenterologists 
already work with PGx, we specifically selected this group for the interview. 
Stakeholders were approached via the available social networks. The snowball 
sampling method was used to contact and interview other relevant stakeholders. 
Sampling was discontinued when saturation of the information was achieved. 
Data collection
Questionnaire. The questionnaire was developed by three members of the 
research team (RLS, WK, MTeich) and face validity was assessed by four experts, 
including two pharmacists (KNMP members) and two geneticists. The geneticists 
were involved to guarantee appropriate language use (i.e. suitable for the PGx 
context). We have provided an English-language version of the questionnaire, 
which is presented in Appendix A. 
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The survey consisted of three main parts, with Part 1 inquiring after general 
characteristics of the responding pharmacist, including sex, age, type of pharmacy 
setting (community, hospital or outpatient), and access to PGx information. In 
Part 2 respondents were asked to rate general statements about PGx we had 
formulated, and in Part 3 to give their views on the importance of various factors 
for the implementation of PGx, which had been derived (by RLS, WK, MTeich) from 
the relevant literature (11-13). The pharmacists rated the statements on a five-
point Likert scale, ranging from 1 (Totally agree) to 5 (Totally disagree), and one 
Yes/No question. One item concerned the costs of testing, with the scale ranging 
from 1 (€25 - €50) to 5 (>€200). The factors pertained to, among other issues, 
education, ICT, costs, and collaboration with GPs. They were also rated on a five-
point Likert scale, here ranging from 1 (Not very important) to 5 (Very important). 
We had added an open question to provide the pharmacists the opportunity to 
introduce additional issues that they thought merited attention. 
Semi-structured interviews. The semi-structured interviews were likewise 
devised to gauge the attitudes towards, knowledge about, and experiences with 
PGx testing of relevant stakeholders to identify potential facilitators of and barriers 
to the implementation of PGx in clinical practice. 
For this purpose we performed an explorative literature search and used Grol and 
Wensing’s Implementation of Change Model to identify relevant factors for PGx 
implementation (18). The model describes different factors and conditions that are 
important for implementation, such as (recent) scientific information, guidelines, 
and best practices, in the order in which these factors become relevant in the 
course of the implementation process. Having selected pertinent factors for our 
study, we drew up an interview manual with open questions that addressed the 
stakeholders’ experiences with PGx, their attitude towards PGx, their expectations 
for the future of PGx, the perceived added value and challenges of PGx testing, 
and their views on potential facilitators and barriers (e.g. scientific evidence, 
guidelines, costs, and knowledge). If necessary, questions were adjusted to a 
stakeholder’s expertise or working field. For instance, for the gastroenterologists, 
a specific example was selected that matched their discipline:  the gene-drug 
interaction Thiopurine S-methyltransferase (TPMT) and thiopurine treatment in 
patients with inflammatory bowel disease (IBD). 
All interviews were audio- recorded. They were interactive and cumulative, which 
means that questions were adapted or added based on information gained 
during earlier interviews. In addition, quotations from earlier interviews were put 
to subsequent stakeholders for verification or refutation. Durations accordingly 
varied from 25 to 60 minutes. The interviews were conducted by two members of 
the research team (AvL and RS) - who had been trained by an expert on qualitative 
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research (MTum) - between April 2017 and June 2017, at a place, date, and time 
convenient for the participant. The interview techniques of the interviewers were 
discussed with the expert on a weekly basis. 
Analysis
Questionnaire. The pharmacists’ baseline characteristics were presented as 
numbers and the corresponding percentages. For the analysis of de data obtained 
for Parts 2 and 3 of the survey,  the Statistical Package for Social Sciences (SPSS), 
version 22.0 for Windows (IBM Corp., Armonk, NY) was used, with opinions and 
perceptions being presented as percentages. The open question was analysed 
by two researchers (RLS, WK) who screened and coded all texts independently to 
identify additional factors. Differences were discussed until consensus was reached.
Semi-structured interviews. For the qualitative analysis we applied the thematic 
analysis method as described by Braun and Clarke (19). The audio-taped interviews 
were transcribed and subsequently coded in Atlas.ti software (ATLAS.ti Scientific 
Software Development GmbH, Berlin, Germany). After each interview, a summary 
was written (AvL) and sent to the stakeholder for validation. Thematic analysis 
was used to determine the different themes that had been discussed with the 
stakeholders. The transcripts were independently coded and discussed by two 
members of the research team (RS and AvL). After reaching consensus on code 
levels, different members of our research team (RS, AvL, WK, MTeich, MTum) 
classified the codes into overarching themes. The content of each theme was 
worked out in detail, named, and defined (RS and AvL). After having completed 
the results section presented below, quotes to illustrate the themes were selected 
(RS and AvL) and translated from Dutch, and reviewed (WK, MTeich and MTum).
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Results
Questionnaire
Of the 3,461 pharmacists contacted, 382 (11.0%) completed the questionnaire. 
Respondent characteristics are presented in Table 1. Half of the respondents were 
female; the mean age of all respondents was 42 years, with most respondents 
(78.0%) reporting to work in a community pharmacy, and 15.8% and 6.2% working 
in a hospital or an outpatient pharmacy, respectively; 58.6% had access to PGx 
information for at least one patient, while 48 (13.5%) pharmacists had actively 
requested PGx information. This latter group was asked to answer additional 
in-depth questions (see Appendix B), which revealed that the PGx information 
mainly concerned the CYP2D6 and CYP2C19 genes and antidepressant and 
antipsychotic drugs, and that the greater majority had used this information to 
optimize treatments, feeling competent to explain the test results to the patients 
concerned. 
Table 1. Baseline characteristics of the respondents (n=382) to the PGx Questionnaire

































a missing n=2; b missing n=21; c missing n=4
Almost all respondents acknowledged that PGx could play a role in finding the 
right drug treatment and the right dosage for individual or subgroups of patients 
to thus prevent ADRs (Table 2). Also, most respondents acknowledged that 
pharmacists should take advantage of PGx information and that they have the 
possibility to request and interpret this information themselves. Preferably, the 
costs of any PGx test should not exceed €100. The respondents differed in their 
views whether patients should control their PGx data and whether they could 
share the information with health-care providers if requested. This disagreement 
was also seen on the question whether PGx testing should be made available for 
all patients within five years. Only half of the respondents thought that PGx would 
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be part of their medication surveillance services and that they would be sharing 
the information with other drug prescribers within that time frame. 







Agree (n, (%)) Totally agree 
(n,(%))
Pharmacogenetics can play a role in the choice of a specific drug.
0 2 (0.5) 12 (3.1) 208 (54.5) 159 (41.6)
Pharmacogenetics can help me determine the right dosage for particular drugs.
0 3 (0.8) 24 (6.3) 208 (54.5) 147 (38.5)
Pharmacogenetic information can be important for the prevention of certain adverse drug reactions.
0 1 (0.3) 30 (7.9) 209 (54.7) 142 (37.2)
Pharmacogenetic information is important to help improve the effectiveness of certain drugs.
0 2 (0.5) 34 (8.9) 212 (55.5) 134 (35.1)
As a pharmacist, I see it as my role to apply pharmacogenetic information
1 (0.3) 5 (1.3) 30 (7.9) 179 (46.9) 167 (43.7)
As a pharmacist, I should be able to order a pharmacogenetic test myself, if I deem this relevant for the 
treatment of my patient.
2 (0.5) 9 (2.4) 42 (11.0) 172 (45.0) 157 (41.1)
As a pharmacist, I should have a role in the interpretation of the results of pharmacogenetic tests.
4 (1.0) 21 (5.5) 69 (18.1) 157 (41.1) 131 (34.3)
Cost considerations are important in my decision to order a pharmacogenetic test (yes/no).
Yes: 290 (75.9) No: 92 (24.1)
What price do you consider reasonable for a pharmacogenetic test? (25 – 50; 50 – 100; 100 – 150; 150 – 200; 
>200)
106 (27.7) 188 (49.2) 76 (19.9) 11 (2.9) 1 (0.3)
Patients should have ownership of their pharmacogenetic profile, and be allowed to share the information 
with their health care provider(s) on request.
19 (5.0) 99 (25.9) 116 (30.4) 106 (27.7) 42 (11.0)
Pharmacogenetic testing should be made available for each patient within 5 years, independent of the 
drug(s) being used.
21 (5.5) 132 (34.6) 112 (29.3) 85 (22.3) 32 (8.4)
Pharmacogenetic testing will be an integral part of the medication surveillance service in my practice within 
5 years.
10 (2.6) 62 (16.2) 112 (29.3) 150 (39.3) 48 (12.6)
I will be sharing pharmacogenetic information with other drug prescribers within 5 years – comparable to 
renal function values.
10 (2.6) 58 (15.2) 85 (22.3) 161 (42.1) 68 (17.8)
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The majority of the respondents indicated that they deemed all the factors 
mentioned in the questionnaire of importance for successful implementation of 
PGx (Table 3). Finally, more than half of the respondents (59.7%) felt that his or her 
practice was currently ready to utilize pharmacogenetic information.
Analysis of the open question did not reveal any additional factors found relevant 
for the advancement of PGx implementation.











Information systems are capable to efficiently process PGx information
0 0 13 (3.4) 146 (38.2) 223 (58.4)
Automated signalling systems that make me aware of the need for PGx profiling in the context of medication 
surveillance
0 4 (1.0) 22 (5.8) 164 (42.9) 192 (50.3)
ICT-supported instruction for the processing of these signals for medication surveillance
0 2 (0.5) 23 (6.0) 201 (52.6) 156 (40.8)
Scientific evidence showing that the application of PGx information helps to optimize drug treatments
0 2 (0.5) 31 (8.1) 196 (51.3) 153 (40.1)
Emperical evidence showing that PGx testing is cost-effective
1 (0.3) 20 (5.2) 89 (23.3) 191 (50.0) 81 (21.1)
Well-defined guidelines on the application of PGx testing in clinical practice, including a detailed description 
of the roles and responsibilities of the healthcare providers involved
1 (0.3) 5 (1.3) 43 (11.3) 196 (51.3) 137 (35.9)
Agreement between the pharmacist and general practitioner on the relevance of / need for PGx testing
2 (0.5) 8 (2.1) 53 (13.9) 200 (52.4) 119 (31.2)
Targeted training for pharmacists
2 (0.5) 4 (1.0) 17 (4.5) 200 (52.4) 159 (41.6)
Supplementary training for pharmacy assistants
3 (0.8) 12 (3.1) 84 (22.0) 219 (57.3) 64 (16.8)
GPs being motivated to work closely together with pharmacists and other healthcare professionals on this 
topic
2 (0.5) 8 (2.1) 56 (14.7) 183 (47.9) 133 (34.8)
Views and consent patients on sharing their PGx information with other clinicians
6 (1.6) 6 (1.6) 86 (22.5) 206 (53.9) 78 (20.4)
Views of patients on the role of the pharmacist in the application of PGx information fot the management of 
their medicinal treatment
6 (1.6) 22 (5.8) 113 (29.6) 165 (43.2) 76 (19.9)













1 (0.3) 10 (2.6) 63 (16.5) 232 (60.7) 76 (19.9)
Clarity about the reimbursement of PGx tests by health insurers
0 4 (1.0) 37 (9.7) 164 (42.9) 177 (46.3)
Reimbursement of pharmacists for PGX-related patient education and counselling additional to regular 
medication surveillance
6 (1.6) 34 (8.9) 105 (27.5) 156 (40.8) 81 (21.1)
Clear information for patients about PGx by the government or KNMP prior to its use 
2 (0.5) 11 (2.9) 70 (18.3) 193 (50.5) 106 (27.7)
PGx Pharmacogenetics; GP General Practitioner; KNMP Royal Dutch Pharmacists Association
Semi-structured interviews
Twelve stakeholders were invited to participate, of whom nine consented: a 
gastroenterologist working in a university medical centre (Interviewee 1), a 
gastroenterologist of a regional hospital (Interviewee 2), a pharmaceutical advisor 
(Interviewee 3) and a medical advisor of two health ensures (Interviewee 4), a 
pharmacist of a community pharmacy (Interviewee 5), a geneticist associated with 
a university medical centre (Interviewee 6), a patient with inflammatory bowel 
disease (IBD) (Interviewee 7), a GP (Interviewee 8), and a policy advisor of the 
KNMP (Interviewee 9). Five of the stakeholders were female. 
In general, all interviewees had a positive attitude towards PGx. They thought that 
PGx would help optimize medication treatment, with the optimization ideally leading 
to fewer ADRs or an increased effectiveness. However, they also identified some 
hurdles for implementation. For instance, interviewees 1-6 and 8 were doubtful 
about making PGx testing available for everyone. It was suggested that, preferably, 
only those patients that were most likely to benefit from PGx should be tested. This 
reasoning was influenced by the extra costs that come with PGx testing. 
Our analysis revealed four main themes that were deemed most relevant for 
successful implementation of PGx in clinical practice: scientific evidence, clinical 
guidelines, the costs associated with PGx, and (gaps in) knowledge. Below, each 
theme will be discussed in detail.
Scientific evidence for PGx
All interviewees stated that relevant and robust evidence of the beneficial effects 
of PGx is crucial for an adequate implementation. 
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Quote Interviewee 3: 
“I think that successful implementation of pharmacogenetics is going to rely on the 
quality of the scientific evidence that can be provided to support its added value.”
However, the stakeholders had different perspectives on the content of this 
evidence. Interviewees 3-6, 8 and 9 mentioned evidence that shows the clinical 
utility of PGx testing, that is that it should have been demonstrated that testing 
and acting on PGx information will indeed reduce the number or severity of known 
side effects or increase the effectiveness of particular gene-drug interactions. They 
believed such evidence is key to convincing healthcare providers and patients to 
accept and apply PGx information to tailor drug treatments. 
Interviewees 1 and 2 indicated that, besides evidence of its clinical utility [19-22], 
evidence was needed supporting the advantages of PGx testing over current 
practices, i.e., substantiation for which patients PGx would be more beneficial than 
standard guideline treatments. Without such data, the interviewees were doubtful 
whether PGx testing would ever become an integral part of daily clinical practice. 
Finally, interviewees 3-6, 8 and 9 also mentioned the importance of evidence 
showing the cost-effectiveness of PGx in clinical practice. Since they were aware that 
genetic testing would imply extra costs, clinically significantly improved treatment 
outcomes and/or fewer side effects were imperative. If cost-effectiveness cannot be 
demonstrated, this will hamper the broader implementation of PGx in clinical practice. 
PGx guidelines
Interviewees 1-6, 8-9 indicated that for successful implementation of PGx uptake 
in clinically useful guidelines is important. These guidelines should provide 
transparent information on when and for whom PGx testing is recommended. 
Again scientific evidence was deemed crucial here. Interviewees 6, 8, and 9 believed 
that clinical guidelines could inform health-care providers and other relevant 
stakeholders on the potential effects of genetic variations in drug response. 
Quote Interviewee 9:
“You have to convince physicians that PGx is useful... As soon as it becomes part of 
new clinical guidelines, things will fall into place of their own accord. Everyone will 
then automatically become aware of it and  consider testing.”
PGx costs 
Interviewees 1-6 and 8-9 referred to the (additional) costs of PGx testing, which 
made them reluctant to order tests for every patient. The weight of the financial 
implications depended on the interviewee’s role and work setting. Interviewees 2, 
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8, and 9 explicitly mentioned that costs would play a role in their decision to order 
PGx tests and that reimbursement should be resolved first. 
Quote Interviewee 2
“Look, from my perspective as a medical specialist costs are never the issue but 
managers, heads of units, to name but a few, actually of course the government, 
keep urging us to work as efficiently and as cost-effectively as possible.“ 
Interviewees 5, 6, 8, and 9 noted that PGx testing would involve additional tasks, 
with their nature differing depending on the stakeholder’s role. For interviewee 
6 this would concern the interpretation of test results and their communication 
to health providers, and for interviewees 5, 8, and 9 advising patients about the 
consequences of the test results for their drug treatment. It was suggested that 
compensation of these added activities might motivate professionals to adopt 
PGx as part of their clinical practice. 
Interviewees 3 and 4 mentioned that, to date, only those interventions that had 
been shown to be (cost-)effective were being reimbursed by health insurers. 
Knowledge of PGx 
Interviewee 2 had conducted research into whether health professionals were 
prepared and ready for PGx. One of the hurdles the study revealed was a knowledge 
gap among health-care providers and, to a lesser extent, among pharmacists and 
clinical chemists. Interviewees 5, 6, 8, and 9 confirmed the existence of a PGx 
knowledge gap in general. 
Interviewees 5, 8, and 9 confided that their knowledge about PGx could be improved, 
especially in terms of its proper use. They claimed to have some knowledge of PGx 
concepts but also stated that this was probably outdated in view of the recent 
advances. Interviewees 1 and 2 asserted to be more familiar with PGx as they had 
been involved in clinical studies and had discussed PGx and its implications with 
colleagues. Interviewee 6 commented that more and more health-care providers 
were asking for information about the principles of PGx and its clinical use. These 
health professionals stated that they did not have sufficient knowledge to decide 
on and order a test, or correctly inform the patients concerned about the results.
As they received increasingly more questions from patients about PGx and its 
potential implications for their drug treatments, interviewees 5, 8, and 9 remarked 
they needed to be better informed about the (new) concepts of PGx, the latest 
guidelines, and recommendations on its proper use in clinical practice in order for 
them to familiarize themselves with PGx and to be able to provide informed advice. 
Lastly, interviewee 7 shared not to have been familiar with PGx until the interview.
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Discussion
Both our questionnaire and interviews revealed that nearly all stakeholders 
that participated in our survey were convinced that personalized medicine, and 
more specifically PGx, could have an important role in optimising drug treatment 
for individual patients. However, they regarded the lack of scientific evidence 
as the key factor to be solved before facilitators should be considered, such as 
recommended treatment optimization and uptake of PGx testing in clinically useful 
guidelines, reimbursement of PGx-related costs, and the (much needed) education 
of  patients and health professionals about the technique, where the evidence 
should at least show its clinical utility, added value, and cost-effectiveness. 
Our findings are in line with the ‘Implementation of Change Model’ Grol and Wensing 
proposed, in which they posit that (new) scientific evidence from systematic 
reviews, clear guidelines, and best practices are required for any implementation 
process to be effective (18). Asking key stakeholders for their views on what type 
of evidence they sought before they would be willing to adopt and implement PGx, 
we uncovered differences in opinions about what sort of scientific evidence was 
(still) needed. As to the specific dose recommendations that have been included in 
certain drug labels, for instance, the evidence pertained to associations between 
a particular ADR and specific genotypes or to the agent being less effective for 
patients with the described genotypes (3-7), which prompted PGx guidelines to 
adapt dosages or switch to another agent to optimize the treatment of these 
patients (5-8). Our study showed, however, that providing these guidelines alone 
was not enough to ensure a wide(r) implementation of PGx in clinical practice, 
as stakeholders crave evidence that shows that the recommended modifications 
actually lead to better treatment outcomes (e.g. fewer ADRs) compared to standard 
care. Evidence showing clinical utility and added value is, as yet, mostly missing (2, 
12, 20-25). At present, there are only a handful of clinical studies that did provide 
such evidence and then only for a small number of specific gene-drug interactions 
(26-34). Most of the participating stakeholders also underscored the importance of 
the substantiation of the cost-effectiveness of PGx testing in terms of health-cost 
savings resulting from fewer ADRs and/or enhanced health benefits. Both types 
of evidence are accordingly considered crucial for any new guidelines and thus 
the uptake of PGx testing in these guidelines. . Eventually, such evidence-based 
clinical guidelines will make health-care providers aware of the relevance and 
(cost-)effectiveness of PGx, and clarify when and for whom testing is beneficial, 
thus (automatically) promoting a wider use of the technique. 
The discrepancy in thoughts about what type of scientific evidence is needed we 
gleaned from our respondents shows the importance of involving a wide array 
of stakeholders in the early stages of research. Only then can we improve and 
foster the use of PGx in clinical practice. Of course, increasingly more evidence is 
112
CHAPTER 6
becoming available as the number of studies investigating the clinical and societal 
relevance of PGx is being stepped up. These studies are preferably randomized 
controlled trials (RCTs), because of the high internal validity. However, this form 
of research is time-consuming and expensives (35). Alternatives that are more 
timely, easier to obtain, and less expensive are (non-randomized) cohort and case-
control studies (prospectively or retrospective, as appropriate) (36, 37). However, 
these designs are also related to a higher risk of bias and associations are harder 
to establish. A  modelling approach could be used to give a prediction about the 
potential impact of an PGx intervention on the potential amount of prevented 
adverse effects and related costs (38).However, the need for clinical trials seems 
(far) less relevant when gene-drug interactions result in very severe side effects 
(i.e. hypersensitive reactions with abacavir), when associations are very strong, 
or when alternative treatments without such genetically driven interactions are 
available (23, 39). 
Grol and Wensing’s implementation model states that after the first stage of 
gathering scientific evidence and formulating guidelines has been concluded, a 
plan of change can be developed (18). However, the stakeholders in our study 
perceived other barriers in current clinical practice that first need to be resolved 
before PGx implementation would be viable. Both in the questionnaire and the 
interviews some stakeholders considered education for themselves and their 
teams important given the gaps in their knowledge that they also perceived 
among other health professionals as well as patients. They mentioned to have 
learned the concepts of PGx, but their knowledge could have become outdated 
due to new innovations and developments. Therefore, education should at least 
include information about the concepts of PGx, how to use it in clinical practice, 
and for which patients it should be used. Clinical guidelines could contribute to 
this knowledge by including these aspects. Also, reimbursement of PGx tests and 
the tasks associated with their interpretation and communication was considered 
an important requisite for a broader application of PGx. Up to now, PGx-related 
costs are being paid for from the hospital or pharmacy budgets (Appendix B). In 
the interviews the health insurers mentioned that only healthcare interventions 
that have proven to be effective will be considered for reimbursement. This 
often means that interventions are part of clinical guidelines. Therefore, if 
PGx testing is included in clinically useful guidelines, this is likely to induce 
health insurers to start reimbursing the costs, which would help foster its use. 
This also applies for a better collaboration between the different professions involved 
in the treatment of a patient, which was seen as a potential barrier. Decisions about 
the optimal treatment strategy should ideally be a result of discussions between the 
different disciplines (GPs, medical specialists and pharmacists) in which everyone’s 
expertise is used. This also applies for the decision to request a PGx test and apply 
this information to optimize the treatment of the patient [9]. Eventually, agreements 
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between pharmacists and physicians about the different roles and responsibilities 
in the use and application of PGx will help to improve the application of PGx. 
Other changes that were eventually considered relevant related to (automatic) 
ICT systems to facilitate the efficient use of the technique and clear patient 
information. 
Our study has several strengths. First, the results from our questionnaire coincided 
with those obtained in the interviews, which suggests that, besides discipline-
specific information, the data we collected also reflect general opinions about 
the relevance and way forward for PGx in clinical practice. Second, compared to 
previous studies, we looked at a wider field of stakeholders and thus the implications 
for a wider array of contexts, providing us with an extensive overview of perceived 
barriers to and facilitators of PGx from a social, organisational, economic, and 
policy-making perspective. Also, by using an interactive, cumulative approach, we 
were able to adapt or extend questions and verify opinions contingent on the 
information gained from other stakeholders. 
As to the study’s limitations, we first need to mention that the questionnaire may 
mostly have invited positive responses as the items only inquired into factors that 
were deemed relevant for the promotion of the use of PGx in clinical practice. 
Moreover, both our stakeholder samples were relatively small. This may have led 
to a false representation of barriers related to implementation of PGx. However, 
the majority of the respondents of the questionnaire indicated the same barriers 
as (very) important. In addition, the same barriers were identified during the 
interviews . Also, we did not interview any stakeholder from the political domain. 
However, since at the time of our survey there was no consensus concerning the 
use of PGx, national policies or regulation was as yet non-existent. Finally, the 
professionals and patient we selected for our interviews may not be representative 
of all stakeholders. However, as most factors raised were mentioned or 
acknowledged by different interviewees from different contexts, we think that our 
results do provide a representative overview of the main obstacles and incentives 
for the clinical implementation of PGx. Since the lack of systematic evidence is an 
international problem, we believe that most of our results are also generalizable 
to international contexts.  
In conclusion, Dutch stakeholders with various health-related backgrounds 
acknowledged the potential of PGx in optimizing individual drug therapies in 
clinical practice. However, for successful implementation, they deemed systematic 
evidence on the clinical utility, added value, and cost-effectiveness of the approach 
indispensable. Evidence-based information on how and for whom the technique 
is/can be made effective, may then convince health professionals and patients of 
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Additional files
Questionnaire
English translation of the Dutch-language pharmacogenetics (PGx) questionnaire for 
KNMP pharmacists (members of the Royal Dutch Pharmacists Association)
Title: The role of pharmacogenetics in the pharmacy 
• The aim of this questionnaire is to gain pharmacists’ 
• opinions about pharmacogenetics
• experiences with pharmacogenetics
• perceived barriers to and facilitators of the implementation of 
pharmacogenetics
Pharmacogenetics (PGx) focuses on finding genetic variations that may be of 
influence on drug response and side effects. Medication surveillance that is based 
on these parameters can facilitate the selection of the right drug and the right 
dosage for the right patients.
Characteristics respondents  Answers
Sex Male Female
Age .. years
Pharmacy setting Hospital pharmacy
Community pharmacy
Outpatient pharmacy
Size of the pharmacy (number of patients) …. patients
Experiences with PGx





Characteristics respondents  Answers
I have actively requested (some of) this PGx information.
If yes: 
Which genes were involved?
Which drugs were involved?
How has the pharmacogenetic information been 
handled? (more than one answer possible) 
How was the PGx test paid for ? (more than one answer 
possible)
I have used the pharmacogenetic information to 
optimize the drug treatment of my patient(s).
I am familiar with the pharmacogenetic 
recommendations in the Medication Monitoring File 
of the G-Standard (national electronic database of 
prescription medication and health-related products) 
and the ‘Kennisbank’ (pharmacogenetic knowledge 
base).
I learned about pharmacogenetics during my formal 
training as a pharmacist and/or during refresher/further 
training courses.
I feel sufficiently competent to explain the results of a 
pharmacogenetic test to my patients.
Yes / No
CYP2D6 / CYP2C19 / CYP1A2 / VKORC1 / 
SLC01B1 / HLA-B*5701 / TPMT / DPYD / 
other
Metoprolol / codeine, tramadol, oxycodon 
/ antidepressants / PPIs / antipsychotics / 
coumarin / antibiotics / fluoropyrimidine/ 
other
Recorded in the patient’s EPR / patient 
labelled with a contraindication in EPR / PGx 
data stored in pharmacy records / other
By the patient / Reimbursed by the health 





Totally disagree / Disagree / Neutral / Agree 
/ Totally agree
Views on PGx
Pharmacogenetics can play a role in the choice of a 
specific drug.
Response options 
Totally disagree / Disagree / Neutral / Agree 
/ Totally agree
Pharmacogenetics can help me determine the right 
dosage for particular drugs.
Pharmacogenetic information can be important for the 
prevention of certain adverse drug reactions.
Pharmacogenetic information is important to help 
improve the effectiveness of certain drugs.
As a pharmacist, I see it as my role to apply 
pharmacogenetic information
As a pharmacist, I should be able to order a 
pharmacogenetic test myself if I deem this relevant for 
the treatment of my patient.
As a pharmacist, I should have a role in the 
interpretation of the results of pharmacogenetic tests.
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Perceived barriers and solutions to the use of PGx
Characteristics respondents  Answers
Cost considerations are important in my decision to 
order a pharmacogenetic test. 
Yes / No
What price (€) do you consider reasonable for a 
pharmacogenetic test?
25 – 50; 50 – 100; 100 – 150; 150 – 200; >200
Patients should have ownership of their 
pharmacogenetic profiles and be allowed to share the 
information with their healthcare provider(s) on request.
Totally disagree / Disagree / Neutral / Agree 
/ Totally agree
Pharmacogenetic testing should be made available for 
each patient within 5 years, independent of the drug(s) 
being used.
Pharmacogenetic testing will be an integral part of the 
medication surveillance service in my practice within 5 
years.
I will be sharing pharmacogenetic information with 
other drug prescribers within 5 years – comparable to 
renal function values.
Implementation of PGx in clinical practice
For successful implementation of pharmacogenetics the 
following factors are important: 
1. Information systems that can efficiently process 
PGx information 
2. Automated signalling systems that make me aware 
of the need for PGx profiling in the context of 
medication surveillance  
3. ICT-supported instruction for the processing of 
signals for medication surveillance 
4. Scientific evidence showing that the application of 
pharmacogenetic information helps optimize drug 
treatments  
5. Empirical evidence showing that PGx testing is 
cost-effective  
6. Well-defined guidelines on the application of PGx 
testing in clinical practice, including a detailed 
description of the roles and responsibilities of the 
health-care providers involved 
7. Agreement between the pharmacist and general 
practitioner on the relevance of /need for PGx 
testing 
8. Targeted training for pharmacists  
9. Supplementary training for pharmacy assistants 
10. GPs being motivated to work closely together with 
pharmacists and other health professionals on this 
topic  
Response categories: 
Not important at all / Not important / 
Neutral / Important / Very important
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Characteristics respondents  Answers
11. Views on and consent from patients on sharing 
their PGx information with other clinicians 
12. Views of patients on the role of the pharmacist 
in the application of PGX information for the 
management of their medicinal treatment 
 
13. Clarity about the costs of PGx testing 
14. Clarity about the reimbursement of PGx tests by 
health insurers  
15. Reimbursement of pharmacists for PGX-related 
patient education and counselling additional to 
regular medication surveillance  
16. Clear information for patients about PGx by the 
government or KNMP prior to its use 
Do you have any suggestions that you deem relevant 




Do you think your pharmacy is ready to use 
pharmacogenetic information?




Are there any experiences, expectations, and/or needs 




Perceived barriers and solutions to the use of PGx
Additional Table 1. Characteristics of the respondents that actively requested PGx information (n=48)
Characteristics N Percentage (%)
Respondents 48 13.5
Which genes were involved? See Additional figure 1
Which drugs were involved? See Additional figure 2
How has the pharmacogenetic information been handled?  
(More than one answer possible)
• EPR
• Patient labelled with a contra-indication in EPR










How was the PGx test paid for?  













I have used this pharmacogenetic information to optimize the 







I am familiar with the pharmacogenetics recommendations of the 







I learned about pharmacogenetics during my formal training as a 







I feel sufficiently competent to explain the results of a 









 Additional fi gure 1 T he genes for which pharmacogenetic information was requested by a pharmacist 
A dditional fi gure 2 Th e drugs for which pharmacogenetic information was requested by a pharmacist 
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The aim of the research presented in this thesis was 1) to evaluate the cost-
effectiveness of the clinical implementation of particular pharmacogenetic 
(PGx) strategies and 2) to identify potential barriers to and facilitators of the 
use of PGx in clinical practice in general. In this final chapter the main findings 
of the various studies are summarized and their implications discussed. Finally, 
recommendations will be given for further research aimed at advancing the 
clinical implementation of PGx. 
Main findings
The first part of this thesis focused on the economic impact of dosage changes or 
drug switches to optimize pharmacological treatments based on PGx information. 
Using decision analytic modelling, in the study reported in Chapter 2 we compared 
the results of a personalized treatment approach of founding the antidepressant 
treatment of patients with (major) depressive disorder on the patient’s genetic 
variation in the CYP2D6 gene, with a no screening (‘one size fits all’) approach. 
We found that, although the PGx-based approach was slightly more expensive 
(incremental costs €91; 95 percentiles: €45; €151), it did result in a slight gain in 
quality adjusted life years (QALYs 0.001; 95 percentiles: 0.0004; 0.002) per patient, 
with an incremental cost-effectiveness ratio (ICER) of €77,406 per QALY gained (95 
percentiles: €22,500 and €377,500). The cost-effectiveness was strongly influenced 
by the impact of the PGx strategy on the prevalence, severity, and prevention of 
adverse drug reactions (ADRs). Due to various uncertainties about the concrete 
impact of PGx screening in this particular case, assumptions had to be made for 
these parameters, which resulted in ICERs that ranged from ‘dominant’ (lower 
costs, more QALYs) to €277,000 (generally considered unacceptable).
In our comparative study reported in Chapter 3, we compared genotype-guided 
treatment allocation to naltrexone or acamprosate as indicated by the genetic 
variation in the OPRM1 gene against random allocation to either treatment option 
in patients with alcohol use disorders, again using decision analytic modelling. We 
showed that the genotype-guided allocation resulted in incremental costs of €66 
(95% CI: -28; 149) and incremental effects of 0.005 QALYs (95% CI: 0.000; 0.011) per 
patient, with an ICER of €13,350 per QALY (95% percentiles: 442,000 to ‘dominant’). 
As the (economic and quality of life) consequences of a relapse are very high (€6,402 
per relapse and disutility of 0.32), we found that adjusting the treatment for only 
a small fraction of patients could still render PGx screening cost-effective. The risk 
ratio for relapse after genotype-guided treatment allocation mainly determined 
its cost-effectiveness as uncertainty in this parameter resulted in a negative 
incremental net monetary benefit (iNMB) (not cost-effective) to positive iNMB 
(cost-effective). The uncertainty was due to the fact that evidence for this risk ratio 
is still contradictory. More evidence is needed to support our conclusions (1, 2). 




analysis performed in the context of the TOPIC trial, a randomized controlled 
trial performed in 30 Dutch hospitals, to contrast pre-treatment genotyping of 
thiopurine S-methyltransferase or TPMT aimed at optimizing individual thiopurine 
treatment to no genotyping in patients with inflammatory bowel disease. 
The results showed that, compared to the control condition, pre-treatment 
genotyping resulted in incremental costs savings of €52 although these were not 
statistically significant (95% percentiles -682; 569), and incremental QALYs of 0.001 
(95% percentiles -0.009; 0.010) per patient. That costs and QALYs did not differ 
significantly for the two patient groups may have been due to the low prevalences 
of the TPMT variant (±10%) and haematological ADRs (±7%) in both groups. 
Furthermore, the disease and the treatment of thiopurines have probably a larger 
impact on the costs (especially productivity losses) and the quality of life than the 
ADR (leukopenia) in the majority of the patients. Furthermore, in the majority of 
the patients the impact of the disease itself and the thiopurine treatment on costs 
(most notably due to loss of productivity) and quality of life was probably larger 
than the effects of ADRs (leukopenia). Summing up, the TOPIC trial demonstrated 
that in patients with the TPMT variant, pre-treatment genotyping resulted in fewer 
haematological ADRs (3) and a comparable quality of life without increasing overall 
health costs compared to no genotyping. 
The research presented in Chapters 2-4 showed that the three PGx strategies 
we examined (CYP2D6 screening to optimize antidepressant treatment, OPRM1-
guided treatment allocation to naltrexone or acamprosate, and TPMT screening 
to personalize thiopurine treatment) all appeared to be cost-effective but did not 
reach conventional levels of statistical significance. Based on the results obtained, 
we concluded that the most important determinants of the cost-effectiveness 
of pharmacogenetics are the prevalence of the genetic mutation screened for, 
the prevalence and the severity of the ADR(s), genotype-phenotype associations 
(penetrance), the accuracy and costs of the genetic test, and the effectiveness and 
costs of the conventional treatment. 
The second part of this thesis centred around the clinical implementation of PGx. 
In the study reported in Chapter 5, we described under which conditions PGx, 
and biomarkers in general, can make healthcare more affordable. As healthcare 
budgets are rising worldwide, the health-economic implications of innovations like 
PGx are important when implementation in clinical practical is considered (4). As 
described above, the findings of our economic evaluations in Chapters 2-4 and 
those documented in the available scientific literature helped us derive the most 
important factors that influence the cost-effectiveness of the use of biomarkers 
in general. We next looked more closely into the concept and usefulness of early 
health technology assessments (HTAs). An early HTA gives stakeholders such as 
health innovators the possibility to explore the room for improvement in current 
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care practices and the likely merits of their innovation in the early stages of its 
development. Depending on this so-called effectiveness gap and information 
about the key determinants of the (cost-)effectiveness of the proposed novel 
technique, innovators can focus their research and development (R&D) efforts on 
those biomarkers that show the most promise in terms of providing a solution 
to the effectiveness gap (5-7). Ultimately, by researching and focusing on the 
most promising biomarkers and promoting the willingness to disinvest in existing 
practices, we can help make healthcare more affordable (8). 
In Chapter 6 we gave an account of our stakeholder survey with which we gauged 
the attitudes towards, knowledge of, experiences with, and views on PGx of 
pharmacists, physicians, health insurers, and a patient in order to identify potential 
barriers to and facilitators of its use in clinical practice. Although the survey showed 
that the stakeholders’ attitude towards PGx was positive and that they felt it could 
have an important role in optimising drug treatments, the majority indicated that 
they were concerned about the lack of robust evidence regarding the clinical 
utility, added value, and cost-effectiveness of the technology. At present, various 
PGx guidelines are being formulated to optimize the treatment of subgroups of 
patients by adapting regimens or agents to specific genetic profiles (9-11) but the 
lack of systematic data hampers the uptake of PGx testing in clinical guidelines and 
thus its implementation in daily practice. Detailed, evidence-based information on 
how and for whom PGx can be effective is likely to convince stakeholders of the 
benefits of PGx over and above usual care. Among the other potential barriers 
that need to be overcome for the implementation of PGx to be successful, the 
respondents mentioned the knowledge gaps among healthcare providers and 
patients, uncertainty about the policies regarding the reimbursement of the costs 
related to PGx testing, and the absence of well-defined modes of collaboration 
between pharmacists and general practitioners. 
Methodological considerations and implications
Our investigations revealed the current uncertainty concerning the (potential) 
relevance of PGx, which partially limited the results of our cost-effectiveness 
studies and explained the stakeholders’ hesitations about the clinical 
implementation of the approach. In the next section, we offer various explanations 
for this uncertainty, highlight some methodological considerations, and discuss 
the potential implications for the implementation of PGx in the clinical setting. 
Expanding the evidence base
One explanation for the uncertainty concerning the potential of PGx is related 
to the lack of scientific evidence showing its clinical utility, in that recommended 




(e.g. fewer ADRs or enhanced health benefits) compared to standard care, which 
was also acknowledged by relevant stakeholders (Chapter 6) and shown in our 
modelling studies (Chapters 2 and 3), where we found that the key parameters 
that determine the cost-effectiveness of the various strategies evaluated all 
hinged on the (lack of) evidence of their clinical utility. In the absence of any robust 
underpinnings, we had to rely on assumptions in our models, which led to the 
wide confidence intervals for the ICERs, precluding any firm conclusions on the 
cost-effectiveness of the interventions under study. In our sensitivity analysis, 
we described the impact of the different assumptions on cost-effectiveness and 
the conditions under which the PGx test might be cost-effective. Clearly, future 
research needs to be directed at finding evidence for these core parameters to 
reduce the uncertainty in modelling studies and thus either confirm or disprove 
our and others’ conclusions. The models we proposed in our studies may then be 
better at predicting the economic consequences of novel PGx strategies and, if 
favourable, facilitate their clinical implementation. 
The debate about which scientific evidence is (still) needed to convince stakeholders 
to adopt and implement PGx is ongoing. There have been several initiatives in which 
guidelines were modified, recommending different dosages or agents based on 
proven associations between a particular ADR and specific genotypes or because an 
agent was found to be less effective for patients with the genotypes described (9-11). It 
was expected that these detailed guidelines in combination with automated signalling 
systems that make prescribers aware of the need for PGx profiling in the context 
of medication surveillance (12) would underscore the usefulness and thus promote 
the use of PGx. However, our study featuring in Chapter 6 showed that providing 
these recommendations alone was not enough to ensure a wide(r) implementation of 
PGx in clinical practice. The stakeholders we interviewed argued that evidence about 
the clinical utility, added value, and cost-effectiveness of these recommendations 
remained crucial. At present, this lack of systematic evidence is hampering the uptake 
of PGx in clinical guidelines on how and for whom PGx is effective. Any new evidence 
should therefore be incorporated in existing or newly formulated clinical guidelines 
to thus emphasize the relevance of PGx testing and convince health professionals 
and patients of its benefits. Potentially, these details will also help overcome some of 
the other perceived barriers of its clinical implementation, such as the knowledge gap 
among healthcare professionals and patients. New guidelines should at least include 
information about the concepts of PGx, its relevance for clinical practice, for which 
patients PGx testing is recommended, offer well-defined modes of collaboration 
between pharmacists and general practitioners, and clarify when tests should be 
requested by which prescribers. Evidently, reimbursement of PGx is indispensable 
for a wider implementation and clearly defined clinical guidelines may persuade 
health insurers to do just that since in the Netherlands formal guidelines are often an 
important criteria for reimbursement (Chapter 6). 
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As mentioned above, studies that systematically document the clinical utility, 
added value, and cost-effectiveness of PGx are quite limited (3, 13-19). Because of 
their high internal validity, randomized controlled trials (RCTs) are the preferred 
mode of research within the field of genetics but they are very time consuming 
and costly, which is often related to the fact that many genetic variants are 
very rare, requiring the inclusion of hundreds of patients in order to ensure 
enough statistical power (20). Therefore, alternative study designs have been 
proposed, each with their own advantages and disadvantages. For instance, (non-
randomized) prospective or retrospective cohort and case-control studies have 
gained increasing attention thanks to new information technologies and large-
scale databases (21, 22). Although more convenient and less costly, such studies 
do have a higher risk of bias and, as they are not performed in well-controlled 
environments, associations are much harder to establish. Adaptive clinical trial 
designs have also been proposed as good alternatives to RCTs (23). They have 
the advantage that they require fewer participants and can be adapted to new 
information in the course of the trial, which can eventually improve the trial’s 
efficiency. By using adaptive randomization, adaptive patient enrolment, and 
adaptive enrichment in PGx studies, researchers are able to select the best 
treatment options for subpopulations with a specific genetic profile, re-estimate 
sample sizes at interim analyses if there is an indication of differential effects across 
the genotypes under investigation, or to withdraw patients from certain subsets, 
for instance to avoid unnecessary exposure to a treatment. The drawback of trials 
like these is their complexity (23). Finally, the modelling approach we applied in 
our studies (Chapters 2 and 3) can also be used to predict the likely impact of 
an intervention on costs and outcomes, for example in terms of the number of 
adverse effects and consequences prevented. When modelling various probable 
options and expected outcomes and projected costs and benefits over time (24), 
one can make use of existing data and combine data from multiple sources, 
rendering the predictions of a certain PGx strategy well-timed. However, the 
design depends on available and reliable information, and when this prerequisite 
is not (fully) satisfied, there is the risk of bias due to the necessary assumptions 
that need to be made (25). Moreover, the results are based on a simplification of 
clinical practice and thus merely offer a reflection of the likely costs and effects. 
Ambiguities in the genotype–phenotype relationship
Uncertainty about the true impact of PGx can also derive from ambiguities in 
the relationship between genotype and phenotype. The discovery of DNA and 
the gene containing all the biological information of an individual, was deemed 
the beginning of a revolution in medical science which would eventually enable 
us to prevent or cure all diseases. These high expectations of genetics have 




not every gene predicts the same disease or triggers the same drug response 
in each person, nor results in the same phenotype. The same holds, at least to 
some degree, for PGx (29). As described in this thesis, recommendations to adapt 
dosages or switch to another agent to optimize the treatment of specific patients 
are based on associations between a particular ADR and specific genotypes or on 
subgroups of patients that have the described genotype(s) showing less response. 
Thus, in patients carrying the CYP2D6 gene the working of certain agents was 
found to be less effective or even toxic due to an abnormal metabolic rate. It was 
recommended to test patients and adjust the dosage or treatment if they were 
found to carry the gene (9-11). However, a study showed that only 4% of the poor 
metabolizers was predicted by their CYP2D6 genotype, implying that ADRs could 
still occur or be missed due to this mismatch (30). As described in Chapter 4, in 
case of TPMT and thiopurine it was recommended to prescribe 0-10% or 50% of 
the standard thiopurine dose for patients with a homozygote and heterozygote 
genotype, respectively. However, further studies showed that in nearly 75% of the 
patients a leukopenia (phenotype) was not predicted by TPMT (genotype) (31). 
The recommendations were all based on the assumption that a specific genotype 
always leads to an assumed phenotype whereas, as these two examples illustrate, 
this may not always be the case, while not every recommended treatment 
adjustment for a specific genotype will result in fewer or less severe ADRs or 
optimal therapeutic blood levels for each patient.
Since in PGx only major, high prevalence variants of a specific gene are tested, not 
all phenotypic variations within the same genotype are covered (32). In the case of 
CYP2D6, patients with an ‘ultra-metabolizer’ profile could have up to 13 copies of 
a functional CYP2D6 gene. DNA tests, which detect only 10 variants, will therefore 
miss some rare variant alleles. As a result, patients with these rare variant alleles 
will go undetected and continue to receive standard treatment and develop 
ADRs arising from mutations in these rare variants (32, 33). Such rare individual 
mutations could collectively play a substantial role in causing ADRs or complex 
diseases, as was shown in the TPMT and CYP2D6 studies (3, 34). 
Furthermore, most diseases and drug responses are not solely dependent on one 
gene (monogenic) or single-nucleotide polymorphism (SNP). In case of CYP2D6 
and antidepressants, various studies observed that, in about 23% of the patients 
genetically classified as non-poor metabolizers, phenoconversion changed their 
clinical response such that it resembled that of patients with poor metabolizer 
genotypes (30, 35). Phenocoversion usually results from factors other than genetic 
factors, such as drug-induced or environmental variability (35). For many years, the 
‘common disease–common variant’ model was predominant. The theory presumes 
that common diseases stem from the effects of combinations of common genetic 
variants (36). Research aimed at identifying these SNPs in so-called genome-wide 
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association studies (GWAS) and resulting reports of associations between deviant 
gene sequences and specific disease risks or drug responses, strengthened the 
model. In this mode of research patients are stratified based on specific SNPs or 
other common disease characteristics. In PGx, stratification is also by genotype, 
whereby the effect of different individual characteristics other than genotypic 
properties is insufficiently acknowledged (37, 38). The definition of personalized 
medicine, “the right therapeutic strategy for the right person at the right time” 
(Chapter 1) underscores the role of the individual patient. We have come to realize 
that patients are individuals whose unique genetic dispositions are shaped by their 
genes as well as their personal histories and environments (39), which means that 
genetic information is just one of the factors that determines their vulnerability 
to diseases and their response to drugs. In his book ‘Gene – an intimate history’, 
Mukheerje describes the circular flow of biological information, whereby 1) DNA, 
proteins and RNA regulate genes, 2) genes encode RNAs, 3) RNAs build proteins, 
4) proteins form/regulate organisms, 5) organisms sense environments, and 6) 
environments influence DNA, proteins and RNA (40). Given this circular flow, the 
author states that, besides research at the individual level, studies looking at the 
influence of social context are essential. This concept that we need to focus on the 
relationships between genotype and phenotype is an expansion of the ‘central 
dogma of molecular biology’ postulated by Crick, which states that DNA makes 
RNA, RNA makes protein, and both DNA and RNA can influence each other or 
themselves (41). 
In conclusion, optimizing pharmacological treatments by stratifying patients based 
on a particular SNP and its associations with a particular ADR does not adequately 
take into account all other relevant factors determining phenotypes and genotypes 
and will only partially improve drug response (33, 38). Also, targeted PGx tests 
could miss rare variant alleles that could have a negative impact on treatment 
outcomes. Finally, in clinical practice tests may still generate false positive or false 
negative results, for example due to allele dropout, with potentially serious or 
even fatal consequences (42). These various disadvantages of genotype testing 
render treatment at the population level less (cost-)effective than expected as the 
technique will not preclude all ADRs or ineffective treatments, possibly explaining 
the current relative successes of PGx. 
Other effective ways to optimize pharmacotherapies
Instead of the current approach of single-gene testing, pre-emptive panel testing 
that covers all known genetic variants may be a more promising alternative. 
Included in a ‘PGx passport’, this information can then be used in combination 
with the existing PGx guidelines to optimize the safety and effectiveness of 49 
commonly prescribed drugs throughout a patient’s lifetime (43). A clear advantage 




for the remainder of the patient’s lifetime. Again, as we as yet have no systematic 
comprehensive data and do not know which of the drugs patients might need 
during their lives, the (cost-)effectiveness of the PGx passport still warrants further 
investigation.
Besides pre-emptive PGx testing, the widely applied therapeutic drug monitoring 
(TDM) approach can still serve to optimize treatment, where some stakeholders 
even question the added value of PGx, as we found in our survey (Chapter 6). 
Obviously, where PGx can be used pre-emptively , where TDM cannot be performed 
until after a drug is administered to the patient, with each method having its 
own purpose to optimize treatment. Thus, pre-emptive PGx testing is highly 
recommended for capecitabine or abacavir as it may prevent lethal complications 
(14, 19, 44), where TDM is useful to manage the use of antidepressants given their 
small therapeutic windows (45). As it is based on the agent’s concentration in the 
blood of a patient, TDM informs the treating clinician of the patient’s phenotype 
or, in other words, the blood concentration is the direct outcome of the circular 
flow of this patient’s biological information. Here, it is the assumption that blood 
concentrations are better indicators of clinical effects than drug dosages (46). 
Based on this information, the dose of the agent can be optimally adjusted to the 
individual patient. This is especially relevant for drugs with a small therapeutic 
range where a small difference in dose or blood concentrations may either lead 
to or prevent ADRs or therapeutic failures. In the case of TPMT and thiopurine 
treatment (Chapter 6), some physicians indeed indicated that TDM offered them 
more information about the treatment’s effect on a patient than PGx would. Still, 
TDM also has some important limitations. For instance, depending on the half-life 
of the drug, it could take some time to determine a patient’s steady state and, 
in case of treatment failure, there still is no explanation why it failed, putting 
the patient at risk of developing ADRs or leaving them to cope with remaining 
symptoms. With respect to TPMT and thiopurines, one of the physicians we 
interviewed deemed the risk of leukopenia acceptable because the patient 
experienced the ADR as mild and the side effect generally does not cause any 
(lasting) harm. When ADRs are potentially more harmful, physicians are more 
reluctant to rely on TDM, especially when it is unclear what the optimal therapeutic 
range is for different drugs, rendering monitoring this way far less effective. For 
instance, since the relationship between blood concentrations and the clinical 
effects of antidepressants is not always clear, it remains difficult to determine the 
optimal dose for specific patients when physicians solely rely on TDM information 
(47). Finally, TDM also does not adequately account for all relevant factors of the 
genotype-phenotype relationship. To truly optimize treatment, it would be ideal to 
combine PGx and TDM, with the former providing information about the potential 
genetic impact on drug response and the latter about the influence of factors such 
as co-medications, diet, impaired organic function, and the like. (47). Together, 
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the two techniques will help us gain more insight into genotype–phenotype 
relationships, which information can be used to find the optimal treatment for 
patients. Future studies should then be directed at determining the clinical and 
economic effects in terms of clinical utility, added value and cost-effectiveness of 
this combination approach.
Future research and recommendations
In this section, several recommendations are given and future research 
goals discussed that could foster the clinical implementation of PGx and thus 
personalized medicine in the coming years. 
More research into the potential of PGx
Previous and our combined studies show that as long as we cannot rely on 
robust evidence and assumptions necessarily determine the parameters of 
any PGx impact models, the effects and cost-effectiveness of PGx will remain 
suppositions only, a fact stakeholders will have to bear in mind when considering 
the implementation of PGx in the shorter term. The consequence could be that 
the costs associated with any pre-emptive genotype testing for all patients will 
likely not be off-set by the prevention of sufficient numbers of ADRs or actual 
enhancements of the effectiveness of pharmacological treatments (Chapters 2-4), 
rendering PGx insufficiently cost-effective compared to usual care, which could 
negatively affect the willingness of health professionals to use the technique for 
individual patients. From an economic perspective, screening subsets of patients 
that share a specific phenotype is more promising as treatment optimization would 
yield more health benefits by preventing ADRs and improving outcomes. This also 
holds for pre-emptive panel testing since the resulting PGx passport could guide 
treatments throughout a patient’s lifetime. Future clinical studies should explore 
the health and economic gains of both strategies. It is evident that PGx is likely to 
be most cost-effective when ADRs are highly prevalent or severe, and/or when 
genotype-phenotype associations are strong and the disease burden as well as 
the indirect burden of health-associated costs can be drastically reduced. The risk 
of PGx not delivering will be limited, for instance, in the case of the HLA-B*5701 
and abacavir interaction (14, 48). Pre-emptive testing is clinically and economically 
justifiable here because of the severity of the side effects, which can even be fatal, 
and the high risk of developing the ADRs, with 50% being genetically explained by a 
certain variant of this gene (Chapter 5). PGx tests for this gene-drug interaction has 
already become standard practice but, of course, for many gene-drug interactions 
the associations and benefits will not be so evident. 
In order to convince potential users and payers (physicians, patients, health 




studies demonstrating its clinical utility and added value (12, 49) compared to 
usual care, where identification of the key determinants of its cost-effectiveness 
will have to show whether projected applications offer ‘value for money’. 
Furthermore, gaining more in-depth knowledge of the influence of rare variant 
alleles and interactions between genes of established gene-drug interactions will 
also help improve the drug response of more patients (32). As explained above, 
this research should ideally take the form of RCTs but alternative study designs 
such as cohort and case-control studies may, despite their disadvantages, also 
be employed where RCTs are not viable (21, 22). Still, PGx impact studies may be 
superfluous as the examples in the study of Chapter 5 showed. This is the case for 
drugs for which robust data are already available (i.e. HLA-B5701 and abacavir (14)), 
for those agents that have severe side effects (i.e. abacavir and codeine), or when 
viable alternative treatments are available (codeine and clopidogrel) (44, 50). PGx 
research should then investigate drugs for which its usefulness is anticipated but 
not yet unequivocally proven, while researchers/developers and manufacturers 
should direct their priorities and efforts to areas where PGx is most promising 
and therefore model the potential effects in as early a stage of the development 
of the test as possible. To bridge the ‘effectiveness gap’, early HTA (Chapter 6) 
may provide insight into the likely health effects that can be gained that are not 
attained with current practices and thus inform R&D decisions. 
Finding the mechanisms underlying genotype-phenotype relationships
Another substantial hurdle to overcome is the relationship between genotype 
and phenotype, where we need to learn more about the mechanisms underlying 
the similarities and differences (29, 51, 52). It has become clear that we cannot 
solely rely on genotype-based profiles to optimize drug treatments and that 
the characteristics of individual patients, their (medical) histories and social 
contexts play a significant role in their drug response. If we are able to identify 
biological pathways of certain phenotypes and can uncover how these pathways 
are disrupted, we can identify targets for (new) therapies or targets that could 
increase the effectiveness of existing strategies (36). The biological pathways 
involved in our metabolism, gene regulation, and the transmission of signals can, 
for instance, be disrupted differently by genetic, epigenetic and/or environmental 
factors (53). In addition to laboratory studies of cells, bacteria, mice and other 
organisms, research comparing the biological pathways of a healthy person 
with the same pathways in a person with a certain disease may shed light on the 
different causes and course of an illness (54). If we know which genes, proteins 
and other molecules are involved in healthy and diseased pathways, this may help 
explain why and what is going wrong in individuals with a certain phenotype and 




In conclusion, our and previous studies have highlighted the many uncertainties 
surrounding the implementation and cost-effectiveness of PGx in clinical practice. 
With the exception of a few cases, today PGx testing is not common practice in the 
Netherlands (14, 19). Before the technique can be more widely implemented, more 
evidence about its clinical utility, added value and cost-effectiveness is needed. 
Although both costly and time consuming, this requires more (prospective) 
studies. If more clinical evidence becomes available, current PGx initiatives such as 
PGx-based recommendations for treatment modifications may need adjusting (5-
7) but we need to be aware that if initiatives are not founded on robust evidence, 
this will negatively affect the willingness of users to adopt the technique and 
hamper the cooperation among stakeholders and, eventually, even compromise 
the sustainability of our healthcare systems in the long run (55). Only when we can 
show that pharmacogenetics can truly improve clinical care at affordable costs, 
with examples of best practices being provided, may health professionals and 
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Personalized medicine tries to improve the risk assessment, diagnosis, prognosis 
and clinical treatment of patients by taking the characteristics of the individual 
patient into account. In this context, pharmacogenetics (PGx) helps optimize 
medication treatment based on genotype testing, thus amending the ‘one size 
fits all’ approach by which the same treatment and the same dosage is used for 
each and every patient, which can cause variable effects in terms of adverse drug 
reactions (ADRs) and/or outcomes and could be one of the explanations for the 
roughly 5% of all ADR-related acute hospitalizations worldwide.
PGx has the potential to optimize drug treatments by preventing ADRs or 
increasing a treatment’s effectiveness. Currently, the labels of at least 300 
approved drugs provide PGx-specific information, and more than 100 dosing 
guidelines are provided. We are, however, still in the early days of implementing 
PGx testing in clinical practice. In theory, the prevention of unwanted side effects 
and an early optimization of medication treatments should improve treatment 
gains and reduce costs, but convincing evidence on the clinical relevance and cost-
effectiveness is crucial for an effective clinical implementation of the approach. 
Health technology assessment (HTA) is the field that studies aspects of the short- 
and long-term consequences of health innovations like PGx. The studies presented 
in this thesis focus on the economic viability of various gene-drug interactions and 
related PGx-based optimization strategies and conditions for successful clinical 
implementation of the technique. 
Part one
The research reported on in the first part of the thesis concerned the economic 
evaluation of several gene-drug interactions. 
In Chapter 2 we investigated the cost-effectiveness of screening for CYP2D6 
and the subsequent adjustment of the antidepressant treatment to patients’ 
metabolizer profiles using a Markov model compared to a no screening strategy 
(the ‘one size fits all’ principle). The pharmacokinetics of many antidepressants, 
either tricyclic antidepressants (TCAs) or selective serotonin re-uptake inhibitors 
(SSRIs, are influenced by the CYP2D6 gene, rendering optimization of the 
treatment for patients with this genotype interesting. Within this model a patient 
had a probability of side effects each week, which was followed by dosage titration 
or treatment switching if necessary. After six weeks the treatment effect of the 
various regimens was determined, with subsequent treatment adjustments if 
necessary. Within a 12-week timeframe, we found that CYP2D6 screening was (1) 
more expensive than the no screening strategy, with incremental costs amounting 




effect gains of 0.001 quality adjusted life years (QALYs; 95 percentiles: 0.0004; 
0.002) compared to no screening. The incremental cost-effectiveness ratio (ICER) 
was € 77,406 per QALY gained (95 percentiles: €22,500; €377,500). Overall, we 
could not unequivocally conclude that screening for CYP2D6 in primary care 
patients using antidepressants is cost-effective, but this was mainly attributable to 
the large uncertainty surrounding our results.
Again using a Markov model, in the study presented in Chapter 3 we evaluated 
the costs and QALYs of genotype-guided treatment allocation based on the 
OPRM1 genotype (with G-allele carriers receiving naltrexone and AA homozygotes 
acamprosate or naltrexone) compared to standard care (random allocation to 
acamprosate or naltrexone) in patients suffering from alcohol-use disorders 
(AUD). Some studies had shown that those patients carrying the G-allele of the 
OPRM1 variant responded better to naltrexone, resulting in reduced relapse rates 
compared to carriers of the AA genotype. Our study showed that, relative to 
standard care, genotype-guided treatment allocation resulted in incremental costs 
of €66 (95% CI: -28 ; 149) and incremental effects of 0.005 QALYs (95% CI: 0.000; 
0.011) per patient (incremental cost-effectiveness ratio of €13,350 per QALY). 
However, depending on the willingness to fund a gain of one QALY, probabilities 
varied between 6 and 79% that the genotype-guided allocation would be cost-
effective. Chapter 3 thus showed that the PGx-based allocation of AUD patients 
to naltrexone can indeed be a cost-effective strategy. Nevertheless, since the 
findings on the effectiveness of OPRM1 genotyping are contradictory, we need 
more robust evidence of the impact of genotype-guided treatment allocation on 
relapse to support our findings. 
In our study reported in Chapter 4, we looked at the effect of thiopurine 
S-methyltransferase (TPMT) -guided thiopurine treatment on healthcare costs and/or 
the quality of life in patients with inflammatory bowel disease (IBD). As clinical studies 
have shown that PGx-guided treatment reduces the risk of haematological ADRs in 
patients treated with thiopurines, we conducted an a priori-defined cost-effectiveness 
analysis in the TOPIC trial, a randomized controlled trial performed in 30 Dutch 
hospitals. Patients diagnosed with IBD (age ≥18 years) were randomly assigned to 
the pre-treatment genotyping condition or the no-screening control group. Total 
costs in terms of volumes of care and QALYs based on EuroQol-5D3L utility scores 
were quantified for the duration of 20 weeks. The results showed that, compared 
to standard treatment, the mean incremental cost savings of baseline genotyping 
amounted to €52 per patient (95% percentiles -682; 569), with the mean incremental 
QALYs being 0.001 (95% percentiles: -0.009; 0.010). Overall, our evaluation showed 
that genotype-guided thiopurine treatment did not increase overall health costs but 
did result in a comparable quality of life in the IBD patients tested and reduced the 




The research presented in the second part of this thesis focused on the clinical 
implementation of PGx. 
In Chapter 5, we presented an overview of whether and when the introduction 
of biomarkers, and thus also PGx, will contribute to a further rise in healthcare-
associated costs or whether the techniques can be exploited to make available 
treatment options more efficient and hence more cost-effective. Making healthcare 
(more) affordable not only depends on the biomarkers in and of themselves 
but even more so on the context in which they are being used. By giving two 
examples from the PGx field, and from our results in Chapter 2-4, we highlighted 
some parameters that have been reported to be of critical importance when it 
comes to cost-effectiveness. Apart from improving outcomes for patients and 
thus healthcare delivery as such, the use of biomarkers should be cost-effective to 
convince sceptics of its added value compared to current standard care. To control 
healthcare expenditure, it is also necessary to disinvest in existing healthcare 
protocols which are less (cost-)effective. Finally, we underscored the usefulness of 
early HTA in this context. The results in these analyses give an indication of how well 
current healthcare is performing and whether there is any room for improvement 
(“the effectiveness gap”). Early HTA can help predict the potential impact of an 
innovation or novel strategy at the very beginning of its development, well before 
implementation is being considered. By starting at such an early stage, the sought-
for benefits of the use of a biomarker can be charted at different levels, with 
dedicated research guiding the development of the most promising biomarkers, 
which can eventually result in improved and (more) affordable healthcare.
In the survey presented in Chapter 6, we explored what various relevant stakeholders 
think are important facilitators of and barriers to the use of PGx in clinical practice, which 
we deemed relevant information if we are to promote the clinical implementation 
of the approach. We adopted a mixed methods design to explore the stakeholders’ 
attitudes towards, knowledge of, and experiences with PGx using a purpose-built 
questionnaire to collect quantitative data and semi- structured interviews to derive 
qualitative data. The stakeholders acknowledged the potential of PGx for optimizing 
individual drug therapies but that for clinical implementations to be effective, providing 
scientific evidence surrounding the clinical utility, added value, and cost-effectiveness 
of PGx detailing its benefits compared to usual practices and how and for whom the 
technique should be used, would be an essential first step. Any scientific evidence 
should then be translated into clinical guidelines. Further, stakeholders and potential 
users improve their knowledge and need to be made more aware of the potential 
advantages of PGx, with the reimbursement of costs related to PGx being another 
obstacle to be overcome. If these recommendations can be fulfilled, this is likely to 




In Chapter 7 the main findings of the research presented in this thesis are 
summarized and discussed, including several methodological issues, and 
recommendations given for further research that will expedite the successful 
implementation of PGx in clinical practice. The studies in Chapters 2-4 showed 
that, although in our economic evaluations PGx appeared to be cost-effective, 
the results were generally not statistically significant. One of the explanations 
for this is the lack of scientific evidence of the clinical utility of PGx, which 
prompted us to make important assumptions in our modelling studies. One of 
our recommendations, and acknowledged by other stakeholders, accordingly is 
to perform more prospective studies to reduce the uncertainty in our economic 
evaluations and convince potential users about the benefits of PGx. Therefore, 
these studies should resolve questions about the clinical utility, meaning that 
recommended PGx-based treatment modifications actually lead to better 
treatment outcomes (e.g. fewer ADRs or enhanced health benefits) compared to 
standard care, added value and cost-effectiveness, most preferably in the format 
of randomized controlled trials (RCTs) because of their high internal validity. 
Prospective or, where appropriate, retrospective cohort and case-control studies 
could also being conducted more frequently. From a health-economic perspective, 
modelling the potential gains of PGx in as early a stage, and promoting the 
willingness to disinvest in existing practices, may provide timely in-depth insights, 
which can help researchers or manufacturers researching and focusing on the 
most promising biomarkers, which can help make healthcare more affordable. 
However, in order to improve the (cost-)effectiveness of (pharmaco)genetic 
testing, the relationship between genotype and phenotype merits more attention. 
Arguably, acting on new information about this relationship would help foster 
personalized medicine. Researchers are accordingly advised to learn more about 
the mechanisms underlying genotype-phenotype relationships and gather more 
patient characteristics, detailing their (medical) histories and social contexts. In 
conclusion, it is crucial that the clinical utility, added value and cost-effectiveness 
of PGx is demonstrated for relevant stakeholders to be won over, for if they do not 
see the need to change usual care and the benefits of the technique, PGx will not 




Personalized medicine probeert de risicobeoordeling, diagnose, prognose en 
klinische behandeling van patiënten te verbeteren door rekening te houden met 
de kenmerken van de individuele patiënt. Farmacogenetica (PGx) helpt in deze 
context de medicatiebehandeling te optimaliseren op basis van het testen van het 
genotype. Dit is tegengesteld aan de 'one size fits all'-benadering, waarbij voor elke 
patiënt dezelfde behandeling en dezelfde dosering wordt gebruikt. Dit kan leiden 
tot verschillende effecten in termen van bijwerkingen en/of uitkomsten, en kan 
een van de verklaringen zijn van de ongeveer 5% van alle bijwerking-gerelateerde 
acute ziekenhuisopnames wereldwijd.
PGx heeft de potentie om medicamenteuze behandelingen te optimaliseren door 
bijwerkingen te voorkomen of de effectiviteit van een behandeling te vergroten. 
Momenteel bieden de labels van minstens 300 goedgekeurde geneesmiddelen PGx-
specifieke informatie, en zijn er meer dan 100 doseringsrichtlijnen verstrekt. We 
bevinden ons echter nog in de vroege fase van de implementatie van PGx-testen in 
de klinische praktijk. In theorie zou het voorkomen van ongewenste bijwerkingen en 
een vroege optimalisatie van medicamenteuze behandelingen, behandeluitkomsten 
moeten verbeteren en kosten verlagen. Maar overtuigend bewijs over de klinische 
relevantie en kosteneffectiviteit is cruciaal voor een effectieve klinische implementatie 
van PGx. Health Technology Assessment (HTA) is het veld dat aspecten bestudeert van 
de korte- en langetermijngevolgen van gezondheidsinnovaties, zoals PGx. De studies 
die in dit proefschrift worden gepresenteerd richten zich enerzijds op de economische 
effecten van verschillende gen-geneesmiddelinteracties en gerelateerde PGx-
optimalisatiestrategieën, en anderzijds op voorwaarden voor succesvolle klinische 
implementatie van deze techniek.
Deel I
Het eerste deel van dit proefschrift beschrijft onderzoek rondom de economische 
evaluatie van verschillende gen-geneesmiddelinteracties. 
In hoofdstuk 2 onderzochten we, met behulp van een Markov-model, de 
kosteneffectiviteit van screening op CYP2D6 en de daaropvolgende aanpassing van 
de behandeling met antidepressiva aan de metabolisatieprofielen van patiënten, 
in vergelijking met een niet-screeningstrategie (het ‘one size fits all'-principe). De 
farmacokinetiek van veel antidepressiva, ofwel tricyclische antidepressiva (TCA's) 
of selectieve serotonineheropnameremmers (SSRI's), wordt beïnvloed door het 
CYP2D6-gen, waardoor optimalisatie van de behandeling voor patiënten met dit 
genotype interessant is. Binnen het model had een patiënt wekelijks kans op 
bijwerkingen, gevolgd door dosis titratie of, indien nodig, verandering van de 




regimes bepaald, met indien nodig daaropvolgende aanpassingen van de 
behandeling. Binnen een tijdsbestek van 12 weken ontdekten we dat CYP2D6-
screening (1) duurder was dan de strategie zonder screening, met oplopende 
kosten van € 91 (95 percentielen: € 45; € 151), maar (2) ook effectiever, met 
incrementele effectwinsten van 0,001 voor kwaliteit gecorrigeerde levensjaren 
(QALY's; 95 percentielen: 0,0004; 0,002), vergeleken met niet-screening. De 
incrementele kosten-effectiviteitsratio (ICER) was € 77.406 per gewonnen QALY 
(95 percentielen: € 22.500; € 377.500). Hierdoor konden we uiteindelijk niet 
eenduidig  concluderen dat screening op CYP2D6 kosteneffectief is bij eerstelijns 
patiënten die antidepressiva gebruiken. Dit was voornamelijk te wijten aan de 
grote onzekerheid rondom onze resultaten. 
In hoofdstuk 3 hebben we opnieuw met een Markov-model de kosten en QALY's 
geëvalueerd van genotype-geleide behandelingstoewijzing op basis van het OPRM1-
genotype (waarbij G-alleldragers naltrexon en AA-homozygoten acamprosaat of 
naltrexon kregen), in vergelijking met standaardzorg (willekeurige toewijzing aan 
acamprosaat of naltrexon) bij patiënten die lijden aan alcoholgebruiksstoornissen 
(AUD). Sommige onderzoeken hebben aangetoond dat patiënten die het G-allel 
van het OPRM1-variant droegen, beter reageerden op naltrexon. Dit resulteerde 
in lagere terugvalpercentages in vergelijking met dragers van het AA-genotype. 
Onze studie toonde aan dat, in vergelijking met standaardzorg, genotype-geleide 
behandelingstoewijzing resulteerde in incrementele kosten van € 66 (95% BI: 
-28; 149) en incrementele effecten van 0,005 QALY's (95% BI: 0.000; 0,011) per 
patiënt (incrementele kosteneffectiviteitsratio van € 13.350 per QALY). Afhankelijk 
van de bereidheid om een  winst van één QALY te financieren, varieerde de kans 
echter tussen 6 en 79% dat de genotype-geleide toewijzing kosteneffectief zou 
zijn. Hoofdstuk 3 toonde dus aan dat de op PGx gebaseerde toewijzing van 
AUD-patiënten aan naltrexon inderdaad een kosteneffectieve strategie kan zijn. 
Maar, aangezien de bevindingen over de effectiviteit van OPRM1-genotypering 
tegenstrijdig zijn, hebben we robuuster bewijs nodig van de impact van genotype-
geleide behandelingstoewijzing op terugval om onze bevindingen te ondersteunen. 
In onze studie in hoofdstuk 4 keken we naar het effect van thiopurine 
S-methyltransferase (TPMT) - geleide thiopurine behandeling op de kosten van 
gezondheidszorg en/of de kwaliteit van leven bij patiënten met inflammatoire 
darmaandoeningen (IBD). Aangezien klinische studies hebben aangetoond 
dat een PGx-geleide behandeling het risico op hematologische bijwerkingen 
vermindert bij patiënten die met thiopurines worden behandeld, hebben we een 
a priori gedefinieerde kosteneffectiviteitsanalyse uitgevoerd in de TOPIC-studie, 
een gerandomiseerde gecontroleerde studie uitgevoerd in 30 Nederlandse 
ziekenhuizen. Patiënten met de diagnose IBD (leeftijd ≥ 18 jaar) werden willekeurig 
toegewezen aan de genotypering vóór de behandeling of de controlegroep 
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zonder screening. De totale kosten in termen van zorgvolumes en QALY's op basis 
van EuroQol-5D3L utility-scores werden gekwantificeerd voor een duur van 20 
weken. De resultaten toonden aan dat, in vergelijking met standaardbehandeling, 
de gemiddelde incrementele kostenbesparing van baseline genotypering € 52 
per patiënt bedroeg (95% percentielen -682; 569), met gemiddelde incrementele 
QALY's van 0,001 (95% percentielen: -0,009; 0,010). Daarmee toonde onze evaluatie 
aan dat genotype-geleide thiopurine behandeling de totale gezondheidskosten 
niet verhoogde, maar wel resulteerde in een vergelijkbare kwaliteit van leven bij 
de geteste IBD-patiënten. Daarnaast verminderde deze strategie het risico op 
hematologische bijwerkingen bij patiënten met een TPMT-variant.
Deel II
Het onderzoek in het tweede deel van dit proefschrift is gericht op de klinische 
implementatie van PGx.
In hoofdstuk 5 hebben we een overzicht gegeven of en wanneer de introductie 
van biomarkers, en dus ook PGx, zal bijdragen aan een verdere stijging van de 
zorgkosten of dat beschikbare behandelingsopties efficiënter, en dus meer 
kosteneffectief, in worden gezet. Zorg (meer) betaalbaar maken hangt niet alleen 
af  van de biomarkers op zich, maar nog meer van de context waarin ze worden 
gebruikt. Met twee voorbeelden uit het PGx gebied en onze resultaten in hoofdstuk 
2-4 hebben we enkele parameters naar voren gebracht waarvan bekend is dat 
ze van cruciaal belang zijn als het gaat om kosteneffectiviteit. Afgezien van het 
verbeteren van de resultaten voor patiënten en dus van de zorgverlening als 
zodanig, zou het gebruik van biomarkers kosteneffectief moeten zijn om sceptici 
te overtuigen van de toegevoegde waarde ervan in vergelijking met de huidige 
standaardzorg. Om de zorguitgaven te beheersen is het ook noodzakelijk om te 
desinvesteren in bestaande zorgprotocollen die minder (kosten) effectief zijn. Ten 
slotte onderstreepten we het nut van vroege HTA in deze context. De resultaten 
van deze analyses geven een indicatie van hoe goed de huidige zorg presteert en 
of er ruimte is voor verbetering (“effectiveness gap”). Vroege HTA kan helpen bij het 
voorspellen van de potentiële impact van een innovatie of nieuwe strategie aan het 
begin van de ontwikkeling ervan, ruim voordat implementatie wordt overwogen. 
Door in zo'n vroeg stadium te beginnen, kunnen de beoogde voordelen van het 
gebruik van een biomarker op verschillende niveaus in kaart worden gebracht, 
waarbij onderzoek vervolgens kan worden gericht op de ontwikkeling van de 
meest veelbelovende biomarkers. Dit kan uiteindelijk resulteren in verbeterde en 
(meer) betaalbare gezondheidszorg.
In het onderzoek in hoofdstuk 6 hebben we onderzocht wat verschillende 
relevante belanghebbenden denken dat belangrijke bevorderende factoren en 




we als relevante informatie om de klinische implementatie van deze benadering 
te willen bevorderen. We hebben een ‘mixed-methods’ studie gebruikt om het 
perspectief van de belanghebbenden ten opzichte van PGx te onderzoeken, 
en daarnaast hun kennis van en ervaringen met PGx. Dit is onderzocht met 
behulp van een speciaal ontworpen vragenlijst om kwantitatieve gegevens te 
verzamelen en semi-gestructureerde interviews voor kwalitatieve gegevens. De 
belanghebbenden erkenden het potentieel van PGx voor het optimaliseren van 
individuele medicamenteuze therapieën. Maar om klinische implementaties 
effectief te laten zijn, zou het leveren van wetenschappelijk bewijs over het 
klinische nut, de toegevoegde waarde en de kosteneffectiviteit van PGx een 
essentiële eerste stap zijn. Hierin zijn details belangrijk over de voordelen ervan 
in vergelijking met de standaard praktijk, en hoe en voor wie de techniek gebruikt 
moet worden. Dit wetenschappelijk bewijs moet vervolgens worden vertaald in 
klinische richtlijnen. Verder zullen belanghebbenden en potentiële gebruikers hun 
kennis moeten verbeteren en meer bewust worden gemaakt van de mogelijke 
voordelen van PGx, waarbij de vergoeding van kosten in verband met PGx een 
ander obstakel is dat moet worden overwonnen. Als aan deze aanbevelingen kan 
worden voldaan, zal dit waarschijnlijk een efficiënt gebruik van PGx in de klinische 
praktijk bevorderen. 
In Hoofdstuk 7 zijn de belangrijkste bevindingen van de onderzoeken in 
dit proefschrift samengevat en bediscussieerd, inclusief verschillende 
methodologische kwesties. Daarnaast worden er aanbevelingen gedaan voor 
verder onderzoek dat de succesvolle implementatie van PGx in de klinische 
praktijk zal versnellen. De onderzoeken in de hoofdstukken 2-4 toonden aan 
dat, hoewel PGx in onze economische evaluaties kosteneffectief bleek te zijn, 
de resultaten over het algemeen niet statistisch significant waren. Een van de 
verklaringen hiervoor is het gebrek aan wetenschappelijk bewijs van de klinische 
bruikbaarheid van PGx, wat ons ertoe aanzette om belangrijke aannames te 
doen in onze modelstudies. Onze aanbeveling, onderschreven door andere 
belanghebbenden, is dan ook om meer prospectieve studies uit te voeren om 
de onzekerheid in onze economische evaluaties te verminderen en potentiële 
gebruikers te overtuigen van de voordelen van PGx. Deze onderzoeken moeten 
vragen over de klinische bruikbaarheid oplossen, oftewel leiden de aanbevolen 
PGx-behandelingsaanpassingen daadwerkelijk tot betere behandelresultaten 
(bijv. minder bijwerkingen of verbeterde gezondheidsvoordelen) in vergelijking 
met standaardzorg.  Daarnaast zullen de onderzoeken zich moeten richten op 
de toegevoegde waarde en kosteneffectiviteit, bij voorkeur in de vorm van 
gerandomiseerde, gecontroleerde onderzoeken (RCT's) vanwege hun hoge 
interne validiteit. Ook zouden prospectieve of, waar van toepassing, retrospectieve 
cohort- en case-control onderzoeken vaker kunnen worden uitgevoerd. Vanuit 
een gezondheidseconomisch perspectief kan het modelleren van de potentiële 
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voordelen van PGx in een vroeg stadium en het bevorderen van de bereidheid om 
te desinvesteren in bestaande praktijken, tijdig belangrijke inzichten opleveren 
voor onderzoekers of fabrikanten. Dit kan helpen bij het onderzoeken van en 
focussen op de meest veelbelovende biomarkers die de zorg betaalbaarder 
kunnen maken. Om de (kosten) effectiviteit van (farmaco) genetisch onderzoek te 
verbeteren, verdient de relatie tussen genotype en fenotype echter meer aandacht. 
Handelen op basis van nieuwe informatie over deze relatie zou wellicht bijdragen 
aan de bevordering van personalized medicine. Onderzoekers wordt daarom 
geadviseerd om meer te weten te komen over de mechanismen die ten grondslag 
liggen aan genotype-fenotype-relaties en meer patiëntkenmerken te verzamelen, 
specifiek over hun (medische) geschiedenis en sociale context. Concluderend is het 
van cruciaal belang dat de klinische bruikbaarheid, de toegevoegde waarde en de 
kosteneffectiviteit van PGx wordt aangetoond zodat relevante belanghebbenden 
kunnen worden overtuigd. Als deze belanghebbenden namelijk niet de noodzaak 
om de gebruikelijke zorg te veranderen en de voordelen van de techniek zien, zal 
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Na al die jaren werk is het dan eindelijk zover, ik kan het dankwoord van mijn 
proefschrift schrijven. Via deze weg wil ik iedereen bedanken die op de een of 
andere manier betrokken is geweest bij de totstandkoming van dit proefschrift. 
Allereerst wil ik mijn promotiecommissie bedanken. Gert Jan van der Wilt, bedankt 
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erg kunnen waarderen. Daarnaast hebben jouw verhalen over de Gezondheidsraad 
of ACP mij geïnspireerd om mijn pad te vervolgen richting beleid en uiteindelijk dus 
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sectie. Blijf dan ook al het goede werk volhouden! Marcia Tummers, jij ook enorm 
bedankt voor de fijne samenwerking. Aan de ene kant even als kamergenoot, 
maar aan de andere kant ook bij de afronding van het laatste hoofdstuk. Het was 
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afdeling en collega’s. Van interessante colloquia tot een gezellige koffiepauze of 
wijnproefavond, dit maakte het werken op de afdeling zeer leerzaam en gezellig. 
Via deze weg wil ik mijn dank overbrengen aan alle co-auteurs die een belangrijke 
bijdrage hebben geleverd aan mijn verschillende artikelen, waaronder Marieke 
Coenen, Arnt Schellekens en Joost Janzing.
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Ook wil ik natuurlijk nog even stil staan bij mijn kamergenoten van kamer 3.20, 
Dorien, Tamara en Richelle. Bedankt voor al jullie gezelligheid en goeie discussies. 
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Dank aan alle collega’s bij de directie GMT (VWS) waar ik de afgelopen jaren mee 
heb mogen samenwerken, en in het bijzonder aan mijn cluster MedTech. Vanaf 
het begin was het al een warm bad waarin ik terecht ben gekomen. In korte tijd heb 
ik al zoveel mee mogen maken, van bezoeken aan patiënten, bij de minister aan 
tafel, tot aan een hoop gestress (maar ook gezelligheid) in de ambtenarenkamer bij 
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omdat je geen pedel mag zijn, krijg jij hier nog een aparte benoeming. Dank voor de 
kans die je mij hebt gegund bij VWS, het is mij tot nu toe nog een waar genoegen 
met jou als mijn manager. En Jan en Ricco, het is altijd met jullie heerlijk filosoferen 
over de toekomst van het MedTech landschap of gewoon over goeie films en series. 
Dat er nog maar vele mooie gesprekken en beleidsplannen mogen gaan volgen.  
De buurmannen aan de Platolaan, Bart S., Tom, Hans, wil ik natuurlijk ook danken 
voor al die eindeloze avonden samen biertjes drinken, eten, films kijken of sporten. 
Het was altijd fijn thuis komen na het werk en weer gezellig onder de studenten te 
zijn. Dat er nog vele gezellige avonden mogen volgen. En dan uiteraard nog extra 
aandacht voor de laatste buurman, Jouke. In al die jaren hebben we mooie dingen 
mee mogen maken en heel veel lol beleefd. Van de ‘zware’ vakantie in Praag tot 
aan de beklimming van de Mont Ventoux, het waren tot nu toe altijd mooie en 
gezellige  avonturen. Dank voor alle gezelligheid en al jouw betrokkenheid in al die 
jaren. Ik heb het ontzettend gewaardeerd, en hopelijk kunnen we nog vele nieuwe 
avonturen beleven. 
Hierbij wil ik ook Ruud bedanken. Wat een reis hebben we al afgelegd: van samen 
de introductie, tot vandaag, en hopelijk binnenkort jouw promotie. We hebben veel 
dingen samen mee mogen maken, en het is altijd weer gezellig om af te spreken 
in Utrecht of Nijmegen om een filmpje te kijken en/of een drankje te doen. En 
dan de man die altijd op de afspraak aanwezig is, Pieter. Of het nou een avond 
voetbal kijken is, een concert bezoek of samen naar festivals gaan, het is elke keer 
weer ontzettend gezellig en zeer geslaagd. Dat er nog maar vele bezoeken mogen 




mee gaat van alle vrienden. Mooi dat we elkaar al sinds de middelbare school niet 
meer uit het oog zijn verloren. Dat we samen nog maar vele sportieve kilometers 
mogen gaan afleggen. Dan als laatste Senior Novus. Heren, het is mij altijd een 
waar genoegen om elkaar tegen te komen, ook al is dat van iedere zondag naar 
een enkele keer per jaar gegaan. We hebben samen al veel mogen beleven, en 
uiteindelijk blijven we altijd weer het volgende zeggen: dHiwo! 
Dan Bart, dat heb je toch maar mooi gered: van ‘stagiair’ die geen raam dicht krijgt 
tot aan mijn paranimf vandaag. Als mijn mede-HTA’er hebben we vele avonden 
lopen filosoferen over de wetenschap, maar natuurlijk ook gewoon films kijken, bier 
drinken en een Iwannetje laten bezorgen. Bedankt voor alle gezelligheid. Dat er nog 
vele mooie avonden mogen volgen, en we natuurlijk hier over een tijdje bij jouw 
promotie kunnen staan. 
Nou Richelle, dan hebben we het allebei toch maar mooi gered die PhD titel na 
al die jaren! Ik ben blij dat jij vandaag ook als mijn paranimf wilt aantreden. Wat 
hebben we al een avonturen beleefd, vele sportkilometers mogen maken, heel veel 
ouwehoeren en bier drinken, en bovenal dikke matties geworden. Bedankt en laten 
we het vooral zo volhouden. En ondanks dat je op veel afstanden dan toch (nog) 
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Lieve Dick, Anoek, Elles en Vincent, wat heb ik toch een fijne broers en zussen. 
Jullie betrokkenheid en gezelligheid is altijd heel erg fijn, en ik reis dan ook altijd met 
plezier af naar Zwolle. Dank jullie wel en dat we samen nog maar mooie nieuwe 
hoogtepunten mogen gaan meemaken. En Dick nog een extra woord voor jou, 
aangezien het altijd erg gezellig is samen concerten en festivals bezoeken, een 
marathon lopen, of eindeloos films kijken en over muziek hebben. Dank voor alle 
gezelligheid, en laten we dat vooral voortzetten!
Allerleukste en liefste neefjes en nichtjes, Joël, Oscar, Lotte, Sophie en …, wat is het 
fijn om jullie in de familie te hebben. Ik hoop dat jullie net zulke mooie dingen mogen 
bereiken en beleven zoals de rest van de familie. Maak gebruik van alle kansen die 
op jullie pad komen, maar geniet bovenal van de dingen die jullie zijn gegund. 
Lieve pa en ma, uiteindelijk was dit boekje niet zonder jullie steun en toeverlaat 
tot stand gekomen. Enorme dank voor al jullie ondersteuning en betrokkenheid 
in al die jaren, of het nou de mogelijkheid tot studeren was of gewoon weer eens 
verhuizen, jullie staan altijd voor mij en de rest van de familie klaar. Zie dit boekje 
dan ook zeker maar als jullie succes! Nu op naar het volgende hoogtepunt. 
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